



# **Auditor's report on Healthcare Activos Yield SOCIMI, S.A.**

**(Together with the annual accounts and directors' report of Healthcare Activos Yield SOCIMI, S.A. for the year ended 31 December 2025)**

***(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)***



KPMG Auditores, S.L.  
Torre Realia  
Plaça d'Europa, 41-43  
08908 L'Hospitalet de Llobregat  
(Barcelona)

## **Independent Auditor's Report** **on the Annual Accounts**

*(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)*

To the shareholders of Healthcare Activos Yield SOCIMI, S.A.

### **Opinion**

We have audited the annual accounts of Healthcare Activos Yield SOCIMI, S.A. (the "Company"), which comprise the balance sheet at 31 December 2025, and the income statement, statement of changes in equity and statement of cash flows for the year then ended, and notes.

In our opinion, the accompanying annual accounts give a true and fair view, in all material respects, of the equity and financial position of the Company at 31 December 2025, and of its financial performance and its cash flows for the year then ended in accordance with the applicable financial reporting framework (specified in note 2 to the annual accounts) and, in particular, with the accounting principles and criteria set forth therein.

### **Basis for Opinion**

We conducted our audit in accordance with prevailing legislation regulating the audit of accounts in Spain. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Annual Accounts* section of our report.

We are independent of the Company in accordance with the ethical requirements, including those regarding independence, that are relevant to our audit of the annual accounts pursuant to the legislation regulating the audit of accounts in Spain. We have not provided any non-audit services, nor have any situations or circumstances arisen which, under the aforementioned regulations, have affected the required independence such that this has been compromised.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



## **Most Relevant Aspects of the Audit**

---

The most relevant aspects of the audit are those that, in our professional judgement, have been considered as the most significant risks of material misstatement in the audit of the annual accounts of the current period. These risks were addressed in the context of our audit of the annual accounts as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these risks.

### Recoverable amount of investments in Group companies (see notes 4.1. and 6)

At 31 December 2025 the Company holds investments in Group companies of Euros 438,207 thousand (which represent 98% of total assets at that date). The recoverable amount of investments in Group companies is considered a relevant aspect of the audit, insofar as these investments represent a very relevant percentage of total assets. The recoverable amount of the investment in Group companies is determined, for those companies in which there is objective evidence of impairment, by applying valuation techniques which often require the exercising of judgement by the Directors and the use of assumptions and estimates. Due to the uncertainty associated with the aforementioned estimates, this has been considered a relevant aspect of the audit.

Our audit procedures included assessing the design and implementation of the key controls relating to the valuation process, evaluating the existence of the evidence of impairment identified by the Company, as well as the methodology and assumptions used to estimate the recoverable amount, which take into account the unrealised gains from the real estate assets that are included in the appraisals made by independent experts. We also involved our valuation specialists to assess the reasonableness of the main assumptions used by the Company. We also assessed whether the disclosures in the annual accounts meet the requirements of the financial reporting framework applicable to the Company.

## **Other Information: Directors' Report**

---

Other information solely comprises the 2025 directors' report, the preparation of which is the responsibility of the Company's Directors and which does not form an integral part of the annual accounts.

Our audit opinion on the annual accounts does not encompass the directors' report. Our responsibility for the directors' report, in accordance with the requirements of prevailing legislation regulating the audit of accounts, consists of assessing and reporting on the consistency of the directors' report with the annual accounts, based on knowledge of the entity obtained during the audit of the aforementioned annual accounts, and assessing and reporting on whether the content and presentation of the directors' report are in accordance with applicable legislation. If, based on the work we have performed, we conclude that there are material misstatements, we are required to report them.

Based on the work carried out, as described in the preceding paragraph, the information contained in the directors' report is consistent with that disclosed in the annual accounts for 2025 and the content and presentation of the report are in accordance with applicable legislation.



## **Directors' Responsibility for the Annual Accounts**

---

The Directors are responsible for the preparation of the accompanying annual accounts in such a way that they give a true and fair view of the equity, financial position and financial performance of the Company in accordance with the financial reporting framework applicable to the entity in Spain, and for such internal control as they determine is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

## **Auditor's Responsibilities for the Audit of the Annual Accounts**

---

Our objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with prevailing legislation regulating the audit of accounts in Spain will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with prevailing legislation regulating the audit of accounts in Spain, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.



*(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)*

- Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves a true and fair view.

We communicate with the Directors of the entity regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

From the significant risks communicated to the Directors of Healthcare Activos Yield SOCIMI, S.A., we determine those that were of most significance in the audit of the annual accounts of the current period and which are therefore the most significant risks.

We describe these risks in our auditor's report unless law or regulation precludes public disclosure about the matter.

KPMG Auditores, S.L.  
On the Spanish Official Register of  
Auditors ("ROAC") with No. S0702

*(Signed on original in Spanish)*

Alejandro Núñez Pérez  
On the Spanish Official Register of Auditors ("ROAC") with no. 15732  
17 March 2026

# Healthcare Activos Yield SOCIMI, S.A.

Annual Report of the Annual Financial Statements of the year ending  
December 31, 2025



**Healthcare Activos Yield SOCIMI, S.A.**

Balance sheet for the financial year ending December 31, 2025 - Figures in thousands of Euros

	Note	December 31, 2025	December 31, 2024
<b>Assets</b>			
Intangible fixed assets	7	-	2
Long-term investments in group and associated companies		438,207	431,945
Equity instruments	6	323,135	338,518
Credits to companies	14	115,072	93,427
<b>Non-current assets</b>		<b>438,207</b>	<b>431,947</b>
Trade and other receivables		940	1,030
Trade receivables, group and associated companies	8 and 14	114	96
Public entities, other	11	826	934
Short-term investments in group and associated companies	8	7,593	5,319
Short-term accruals	8	42	29
Cash and cash equivalents		1	1
<b>Current assets</b>		<b>8,575</b>	<b>6,379</b>
<b>Total assets</b>		<b>446,782</b>	<b>438,326</b>

**Healthcare Activos Yield SOCIMI, S.A.**

Balance sheet for the financial year ending December 31, 2025 - Figures in thousands of Euros

	Note	December 31, 2025	December 31, 2024
<b>Net equity and Liabilities</b>			
Net equity	10	396,428	387,654
Capital		174,194	174,194
Share premium		85,593	85,593
Other equity holders' contributions		117,702	116,848
Reserves		1,747	717
Profit/(loss) for the period		17,192	10,303
Interim dividend		(12,799)	(8,656)
<b>Net equity</b>		<b>383,628</b>	<b>378,998</b>
Long-term debts	9	28,797	39,815
Amounts payable to credit institutions		28,797	39,815
Payable to group and associated companies	9 and 14	21,566	17,038
<b>Non-current liabilities</b>		<b>50,363</b>	<b>56,852</b>
Short-term debts		10,768	554
Amounts payable to credit institutions	9	10,768	554
Payable to group and associated companies	9 and 14	57	-
Trade and other payables		1,966	1,921
Sundry creditors	9	625	832
Other debts with public entities	11	1,340	1,089
<b>Current liabilities</b>		<b>12,791</b>	<b>2,475</b>
<b>Equity and Liabilities</b>		<b>446,782</b>	<b>438,326</b>

## Healthcare Activos Yield SOCIMI, S.A.

### Profit and Loss Account of the financial year ending 31 December 2025 - Figures in thousands of Euros

Profits and Losses	Note	2025	2024
Turnover	12 and 14	20,694	14,432
Other operating income	12	204	273
Other operating expenses	12	(378)	(667)
Amortisation and depreciation	7	(2)	(3)
<b>Results from operating activities</b>		<b>20,518</b>	<b>14,035</b>
Financial income		-	1
Finance charges		(3,325)	(3,733)
Arising from amounts due to group and associated companies	14	(1,076)	(756)
Arising from amounts due to third parties	9	(2,250)	(2,977)
<b>Financial profit</b>		<b>(3,325)</b>	<b>(3,732)</b>
<b>Profit/(loss) before income tax</b>		<b>17,192</b>	<b>10,303</b>
Tax on profits	11	-	-
<b>Financial year result</b>		<b>17,192</b>	<b>10,303</b>

**Healthcare Activos Yield SOCIMI, S.A.**

Consolidated Statement of Changes in Net Equity for the financial year ending  
December 31, 2025 - Figures in thousands of euros

**A) STATEMENT OF REVENUES AND EXPENSES**

	2025	2024
A) Profit and Loss Account Result	<b>17,192</b>	<b>10,303</b>
B) Total revenue and expenses charged directly to equity	-	-
C) Total amount transferred to the profit and loss account	-	-
<b>TOTAL ACKNOWLEDGED REVENUES AND EXPENSES</b>	<b>17,192</b>	<b>10,303</b>

**Healthcare Activos Yield SOCIMI, S.A.**

Consolidated Statement of Changes in Net Equity for the financial year ending December 31, 2025 – Figures in thousands of euros

**B) TOTAL STATEMENT OF CHANGES IN EQUITY**

	Share Capital	Share premium	Other equity holders' contributions	Reserves	Financial year result	Interim dividend	Total net Equity
<b>Balance at December 31, 2023</b>	<b>174,194</b>	<b>85,593</b>	<b>106,694</b>	<b>161</b>	<b>5,550</b>	<b>(3,936)</b>	<b>368,257</b>
Total recognised income and expenses	-	-	-	-	10,303	-	10,303
Transactions with equity holders: (note 10):							
Capital increase	-	-	17,699	-	-	-	17,699
Distribution of dividends	-	-	(7,545)	-	-	(9,715)	(17,260)
Other changes in equity	-	-	-	555	(5,550)	4,995	-
<b>Balance at December 31, 2024</b>	<b>174,194</b>	<b>85,593</b>	<b>116,848</b>	<b>717</b>	<b>10,303</b>	<b>(8,656)</b>	<b>378,998</b>
Total recognised income and expenses	-	-	-	-	17,192	-	17,192
Transactions with equity holders: (note 10):							
Other equity holders' contributions	-	-	5,359	-	-	-	5,359
Distribution of dividends	-	-	(4,505)	-	(617)	(12,799)	(17,921)
Other changes in equity	-	-	-	1,030	(9,686)	8,656	-
<b>Balance at December 31, 2025</b>	<b>174,194</b>	<b>85,593</b>	<b>117,702</b>	<b>1,747</b>	<b>17,192</b>	<b>(12,799)</b>	<b>383,628</b>

## Healthcare Activos Yield SOCIMI, S.A.

### Cash Flow Statement for the financial year ending December 31, 2025 - Figures in thousands of Euros

Cash flow from operations	Note	December 31, 2025	December 31, 2024
<b>1. Cash flows from operating activities</b>			
Pre-tax financial year result		17,192	10,303
Adjustments to the profit or loss			
Amortisation and depreciation		2	3
Finance charges	9	2,250	2,977
<b>Adjusted profit/(loss)</b>		<b>19,444</b>	<b>13,283</b>
Increase/(decrease) in current assets and liabilities			
Increase/(decrease) in payables		(207)	(54)
Increase/(decrease) in other assets and liabilities		838	772
Interest payments		(2,098)	(2,921)
<b>Total net cash flows from operating activities</b>		<b>17,978</b>	<b>11,079</b>
<b>2. Cash flows from investing activities</b>			
Investments in			
Group and associated companies	6	15,383	(24,048)
<b>Total net cash flows from investment activities</b>		<b>15,383</b>	<b>(24,048)</b>
<b>3. Cash flow from financing activities</b>			
Payments for dividends and remunerations from other equity instruments	10	(17,921)	(17,260)
Capital increase and other equity holders' contributions	10	5,359	17,699
Debt repayment	9	(29,009)	(12,500)
Obtainment of new financing with credit institutions	9	27,563	19,172
Redemption and repayment of debts with group companies	14	(19,352)	5,805
<b>Total net cash flows from financing activities</b>		<b>(33,360)</b>	<b>12,916</b>
<b>4. Net increase /reduction in cash and cash equivalents</b>			
		-	(53)
Cash or cash equivalents at start of financial year		1	54
Cash and cash equivalents at end of year		1	1

## Healthcare Activos Yield SOCIMI, S.A.

### Notes to the Annual Accounts for the financial year concluding on December 31, 2025

#### 1. Activity of the Company

Healthcare Activos Yield Socimi, S.A. was incorporated on February 1, 2019 under the corporate name of Roldania Investments, S.A. before the notary Fernando Fernández Medina. On July 26, 2019, the corporate domicile of the Company was relocated to Paseo de la Castellana, 45 6<sup>a</sup> 28046, Madrid. Later, on September 18, 2019, the company was named Healthcare Activos Yield SOCIMI, S.A. On September 17, 2024, the corporate domicile of the Company was relocated to Calle Serrano, 21 6<sup>a</sup> 28001, Madrid.

On September 13, 2019, the General Shareholders' Meeting of the company agreed on the adoption of the special tax regime of "SOCIMI", defined in Law 11/2009, of 26 October, which regulates Publicly-traded Investment Corporations in the Real Estate Market, with effect for the tax periods beginning 1 February 2019 (date of incorporation of the Company).

The Company and its subsidiary companies are part of the first leading platform in Spain for specialised investment in real estate assets at the service of the social/healthcare sector, including nursing homes, hospitals and clinics.

The Company's corporate purpose, pursuant to its by-laws, is as follows:

- > the acquisition and promotion of real estate of an urban nature for its lease, including the activity of renovation of buildings in the terms established in Law 37/1992, of 28 December, on Value-Added Tax;
- > holding shares in the capital of other publicly-traded real estate investment companies (SOCIMIs), or in other entities that do not reside in Spanish territory that have the same corporate purpose as them, and are subject to a regime similar to the one established for SOCIMIs as concerns the mandatory, legal or statutory policy for the distribution of profits.
- > holding stakes in the capital of other entities, whether or not they are residents in Spanish territory, who have as their main corporate purpose the acquisition of real estate of an urban nature for its lease, and that are subject to the same regime that is established for SOCIMIs as concerns the mandatory, legal or statutory policy for distribution of profits, and that meet the investment criteria required for such companies; and
- > holding shares or stakes in Collective Real Estate Investment Institutions regulated in Law 35/2003, of 4 November, on Collective Investment Institutions, or any rule replacing it in the future.

Along with the economic activity derived from the main corporate purpose, the Parent Company may conduct other additional activities, with any whose income totals, overall, less than 20% of the Company's total revenue in a given tax period, or those that may be considered complementary pursuant to the applicable law at any time.

The listed activities may also be totally or partially, conducted by the Parent Company, indirectly, through holdings in other companies of identical or similar purpose.

The tax regime of the Parent company and most of its subsidiaries is regulated by Law 11/2009, of 26 October, later modified by Law 16/2012, of 27 December, which regulates Publicly-traded Investment Corporations in the Real Estate Market (SOCIMI).

Article 3 establishes the investment requirements for this type of Companies, which are:

1. The SOCIMI must have invested at least 80% of the value of the asset in real estate of an urban nature intended for the lease, in land for the promotion of real estate to be used for that purpose, provided that the promotion is initiated within three years following its acquisition, as well as in shares in the capital or equity of other entities that are referred to in Section 1, Article 2 of the aforementioned Law.

The value of the asset will be determined by the average of the individual quarterly balance sheets for the financial year. The SOCIMI may calculate this value to replace the book value with the market value of the elements that make up these balance sheets, which would be applied to all balance sheets for the financial year. For these purposes, and if applicable, the money or credit claims from the transfer of such real estate or shares that have been made in the same or prior financial year will not be calculated when, in the latter case, the reinvestment period referred to in Article 6 of the aforementioned Law has not passed.

This percentage will be calculated based on the average of the consolidated balance sheet in the event that the company is the parent company of a group according to the criteria established in Article 42 of the commercial code, regardless of residence and the obligation to formulate consolidated annual financial statements. Said group shall be made up exclusively of the SOCIMI and the rest of the entities referred to in section 1 of Article 2 of said Law.

2. Likewise, at least 80% of the income of the tax period corresponding to each financial year, excluding those derived from the transfer of the shares and the real estate assets both subject to the fulfilment of their main corporate purpose, once the maintenance period referred to in the following section has elapsed, must come from the leases of real estate and from dividends or interests in the profits from said shares.

This percentage will be calculated on the consolidated result in the event that the company is the parent company of a group according to the criteria established in Article 42 of the Commercial Code, regardless of residence and the obligation to formulate consolidated annual financial statements. Said group shall be made up exclusively of the SOCIMI and the rest of the entities referred to in section 1 of Article 2 of said Law.

3. The real estate that makes up the assets of the company must remain leased for at least three years. For the purposes of the calculation, the time that the properties have been offered under lease will be added, with a maximum of one year.

The term shall be calculated:

- a. In the case of real estate that appears in the equity of the Company before the time of joining the regime, from the start date of the first tax period in which the special tax regime established in said Law is applied, provided that on that date the property was leased or offered under lease. Otherwise, the provisions of the following letter shall apply.
- b. In the case of real estate promoted or acquired later by the Company, from the date on which it was leased or offered in lease for the first time.
- c. In the case of shares or equity interests in the capital of entities referred to in section 1 of article 2 of said Law, they must remain in the assets of the Company for at least three years from their acquisition or, where appropriate, from the beginning of the first tax period in which the special tax regime established in said Law is applied.

In addition, Law 11/2009 establishes the following requirements in Articles 4 and 5:

1. The shares of the SOCIMI must be registered and be admitted for negotiation in a regulated market or in a multilateral Spanish trading system or in that of any other Member State of the European Union or the European Economic Area, or in a regulated market of any country or territory with which there is effective exchange of tax information, uninterrupted throughout the tax period.
2. The SOCIMI will have a minimum share capital of 5 million euros. There may be only one class of shares. When the Company has opted for the special tax regime established in said Law, it must include in the company's name the indication "Sociedad Cotizada de Inversión en el Mercado Inmobiliario, Sociedad Anónima", or its abbreviation, "SOCIMI, S.A.".
3. In addition, as described in Article 6 of Law 11/2009, of 26 October, which regulates Publicly-traded Investment Corporations in the Real Estate Market, the SOCIMI and entities residing in the Spanish territory in which they participate that have opted for the application of the special tax regime established by said Law, are required to distribute dividends to their shareholders, once the corresponding commercial obligations have been fulfilled, the profit obtained in the financial year, its distribution must be agreed upon within six months following the conclusion of each financial year, in the following form: (i) 100% of the profits from dividends or interests in profits distributed by the entities subject to said regime; (ii) 50% of profits arising from the transfer of real estate and shares or equity units, made after the deadlines established in the investment requirements have elapsed, with the rest of said profits being reinvested within the three years following said transfer, and failing that, must be distributed in full; and (iii) at least 80% of the rest of the profits obtained.

As established in Note 10, during the 2024 financial year, the Parent Company distributed interim dividends of the results of the 2024 financial year. In the 2025 financial year, the company distributed interim dividends for the profits of the 2025 financial year.

As established in the First Transitory Provision of Law 11/2009, of 26 October, which regulates Publicly-traded Investment Corporations in the Real Estate Market, it may be decided to apply the special tax regime in the terms established in article 8 of said Law, even when the requirements therein are not met, provided that such requirements are met within two years following the date of the option to apply said regime.

In this regard, as of December 31, 2025 and 2024, of the requirements established by Law 11/2009, of 26 October, which regulates the Publicly-traded Investment Corporations in the Market, the Company complies with all the conditions mentioned therein.

The Board of Directors of the Company monitors compliance with the requirements established in said Law, with the objective of maintaining the aforesaid tax regime, estimating that said requirements will be fulfilled in the terms and deadlines set, and recognising the corporate income tax for the financial year in that sense.

The Company is the head of a group of subsidiary entities, and in accordance with the current legislation, is required to separately prepare consolidated annual financial statements. The profit and consolidated net equity of the Group totalled 35,331 and 488,654 thousand euros, respectively (8,976 and 468,191 thousand euros, respectively, in the 2024 financial year).

## **2. Basis for presentation of annual financial statements**

### **2.1.TRUE AND FAIR VIEW**

The annual financial statements have been prepared from the Company's accounting records, and are presented in accordance with the General Accounting Plan, approved by Royal Decree 1514/2007, of 16 November, which approves the General Accounting Plan and the mandatory accounting legal provisions, in order to show a fair representation of the equity, the financial position and the results of the company during the corresponding financial year.

The Company's annual financial statements for financial year 2025 have been formulated by the Company's Board of Directors on March 12, 2026, and will be submitted for approval by the General Meeting of Shareholders, it being estimated that they will be approved without any modification.

### **2.2 ACCOUNTING PRINCIPLES NOT APPLIED**

The accounting principles and valuation rules used by the Company to prepare the annual accounts of the financial year are the same ones applied for the Financial Statements for the financial year ending at 31 December 2024.

### **2.3 FUNCTIONAL CURRENCY**

The figures obtained in the annual financial statements are expressed in thousands of euros.

### **2.4. CRITICAL ASSESSMENT ASPECTS AND ESTIMATION OF UNCERTAINTIES**

There are no relevant data on the estimation of uncertainty at the closing date of financial year, as there has not been associated any significant risk that could involve significant changes in the value of assets or liabilities in the following financial year.

The management estimates that there are no risks of significant uncertainties related to events or conditions that may give rise to significant doubts about the possibility that the company will continue to operate normally.

### **2.5. COMPARISON OF THE INFORMATION**

The annual financial statements are presented for comparative purposes, with each of the items of the Balance Sheet and the Profit and Loss Account, the Consolidated Statement of Changes in Net Equity, the Consolidated Cash Flow Statement and the Consolidated Annual Report, in addition to the figures of the 2025 financial year, those corresponding to the previous financial year of 2024, which were approved by the General Meeting of Shareholders on April 29, 2025.

## 2.6 FINANCIAL RISK MANAGEMENT

The Company efficiently manages its financial risks with the aim of having an adequate financial structure that allows it to maintain high levels of liquidity, minimise borrowing costs, reduce volatility due to changes in capital and ensure compliance with its business plans. The Company's management of financial risk is centralized in its Financial Management, which has established the necessary mechanisms to control exposure to the main risks that could have an impact on the Company's operations, described in the following paragraphs:

**Market risk:** Market risk is the risk that the fair value or future cash flows of a financial instrument fluctuate due to changes in market prices. The Company's market risks arise from open positions in assets and liabilities that accrue interests, to the extent they are exposed to general and specific movements of the market. The administration sets limits to interest rate risk exposure that could be acceptable, which are regularly monitored (see details below). However, the use of this focus does not prevent losses outside these limits in case of more significant market movements.

**Interest rate risk:** The Company's interest rate risk arises from long-term borrowings. External resources issued at variable rates expose the Company to cash flow interest rate risk.

**Liquidity risk:** Liquidity management is carried out by the Group's Finance Department, which makes the necessary cash forecasts and follows up on the annual budget and liquidity needs to guarantee compliance with its financial obligations. The Company is not significantly exposed to liquidity risk due to the maintenance of sufficient cash and the availability of financing to deal with the cash outflows necessary in its usual operations.

**Counterparty risk:** The Company mitigates this risk by using top-tier financial institutions to arrange its financial operations.

**Credit risk:** The Company has policies to ensure that sales are made to customers with an adequate credit history. The value correction for customer insolvency involves the review of individual balances based on customer credit quality, current market trends and historical analysis of aggregate insolvencies. At December 31, 2025 and 2024, the Company did not present any significant recognised impairments, as there were not any mature balances linked to credit risk.

## 2.7 GOING CONCERN PRINCIPLE

The Group has a solid liquidity position, backed by recurrent and predictable generation of cash deriving, and non-disposed corporate lines of credit and financing, that is sufficient to cover its short-term obligations.

The structure of current assets and liabilities at the end of the financial year is aligned with a business model based on the accounting classification of certain financial items pursuant to accounting regulations, a common circumstance in real estate property companies. This configuration is consistent with the normal operations of the sector, and enables the Company to conduct its activity with total normality, supported by stable and recurrent cash flows.

### 3. Distribution of results

#### 3.1 PROPOSED APPLICATION OF PROFIT

The Board of Directors of the Company will propose to the General Meeting of Shareholders the application of the results of financial year 2025 detailed below:

Euros	Basis of distribution	Distribution
<b>Basis of distribution:</b>		
Profit/(loss) for the financial year 2025	17,192,273.92	-
<b>Application to:</b>		
Legal reserve	-	1,719,227.39
Distribution of dividends	-	15,473,046.53
<b>TOTAL</b>	<b>17,192,273.92</b>	<b>17,192,273.92</b>

The distribution of the Company's results for the financial year ending 31 December 2024, approved by the General Meeting of Shareholders, was as follows:

Euros	Basis of distribution	Distribution
<b>Basis of Distribution:</b>		
Profit/(loss) for the financial year 2024	10,302,636.95	-
<b>Application to:</b>		
Legal reserve	-	1,030,263.69
Distribution of dividends	-	9,272,373.26
<b>TOTAL</b>	<b>10,302,636.95</b>	<b>10,302,636.95</b>

### 4. Recording and valuation rules

The valuation standards used by the Company in the preparation of its consolidated annual financial statements for the year ended 31 December 2025, in accordance with those established by the General Accounting Plan, are the following:

#### 4.1 FINANCIAL INSTRUMENTS: ASSETS

##### Initial recognition

Financial assets are recognised in the balance sheet when their acquisition is carried out and are initially recorded at fair value, including operating costs in general.

The financial assets held by the Company are classified as:

### **Financial assets held for trading**

Assets whose acquisition originates with the purpose of selling them in the short term. It is initially valued at fair value and subsequently at its amortized cost.

### **Investments in group and associated companies, and multigroup**

Group companies are considered those over which the Company, directly or indirectly, through subsidiaries, exercises control in the terms laid down in Art. 42 of the Commercial Code, or when companies are controlled by any means by one or several natural or legal persons that act jointly or are under a single management by agreements or statutory clauses.

Associated companies are considered those over which the Company, directly or indirectly, through subsidiaries, exercises significant influence. Significant influence is the power to intervene in the decisions of financial and operating policy of a company, without this implying the existence of control or joint control over said company. Existence of significant influence is assessed considering for these purposes the potential voting rights that can be exercised or converted at the end of the financial year, and also considering the potential voting rights held by the Company or the other company.

Multigroup companies are considered those managed jointly by the Company or one or some of the group companies, including entities or dominant natural persons, and one or several third parties from outside the group.

Investments in group associated and multigroup companies, are initially recognised at cost, which is equivalent to the fair value of the consideration delivered, including, for investments in associated and multigroup companies, the transaction costs incurred. These are later assessed at cost, minus the accrued amount of valuation adjustments for impairment.

### **Loans and collection items**

These correspond to credits (commercial or non-commercial) originated by the Company in exchange for supplying cash, goods or services directly and whose collections are of a determined or determinable amount and that are not traded in an active market. They are subsequently valued at their amortized cost by recognising the interest accrued based on their effective interest rate in the income statement.

The Company applies impairment criteria to those customers covered by an insurance entity, to the extent that the customer debts exceed 180 days from the expiration date for the amount of the uninsured part, and to those customers not insured when they exceed 180 days from the expiration date.

### **Cash and cash equivalents**

Under this heading of the attached balance sheet, cash is recorded in cash and banks, sight deposits and other highly liquid short-term investments that are quickly cash-realizable and have no risk of changes in value.

### **Investments held until maturity**

Investments held until maturity are securities representing debt with a fixed maturity date, fixed or determinable collections, which are traded in an active market and which the Company has the effective intention and ability to hold until maturity, other than those classified in other categories. The valuation criteria applicable to financial instruments classified in this category are those applicable to loans and receivables.

### Disposal of financial assets

The Company derecognises a financial asset, or part thereof, when the contractual rights to the cash flows of the financial asset expire or are assigned, it being necessary to substantially transfer the risks and benefits inherent in its ownership.

The disposal of a financial asset in its entirety implies the recognition of results for the difference between its book value and the sum of the consideration received, net of transaction expenses, including the assets obtained or liabilities assumed and any deferred profit or loss on consolidated recognised income and expenses in the shareholders' equity.

### Impairment of the value of financial assets

A financial asset or group of financial assets is impaired and an impairment loss has occurred, if there is objective evidence of impairment as a result of one or more events that have occurred after the initial recognition of the asset and that event or events causing the loss to have an impact on the estimated future cash flows of the financial asset or group of assets, which can be reliably estimated.

The Company follows the criteria of recording the timely valuation corrections for impairment of loans and receivables and debt instruments, when there has been a reduction or delay in estimated future cash flows, caused by the debtor's insolvency.

Likewise, in the case of equity instruments, there is an impairment in value when there is a lack of recoverability of the book value of the asset due to a prolonged or significant decrease in its fair value.

## 4.2 FINANCIAL INSTRUMENTS: LIABILITIES

Financial liabilities, including trade creditors and other accounts payable, that are not classified as held for trading or as financial liabilities at fair value with changes in the profit and loss account, are initially recognised at their fair value, minus, where appropriate, transaction costs that are directly attributable to the issuance thereof. After initial recognition, liabilities classified under this category are valued at amortized cost using the effective interest rate method.

The financial liabilities, for valuation purposes, are classified into the following categories:

- Debits and items payable: The debits for commercial transactions, which have originated in the purchase of goods and services for traffic transactions, and the debits for non-commercial transactions, which, not being derivative instruments, have no commercial origin, have been included. These financial liabilities have been initially valued at their fair value, and subsequently, at their amortized cost.
- Financial liabilities held for trading: Includes liabilities issued mainly for the purpose of repurchase in the short term, liabilities that are part of a portfolio of financial instruments identified and managed jointly, when there is evidence of recent actions to obtain short-term profits, and finally derivative financial instruments that are not contracted as financial guarantees, nor have been designated as hedging instruments. These liabilities have been valued at their fair value both initially and subsequently with allocation to the profit and loss account.
- Bank loans and overdrafts that accrue interest are accounted for at the amount received, minus direct issue costs. Financial expenses, including premiums payable in settlement or reimbursement and

direct issuance costs, are accounted for at the accrual criteria in the profit and loss account using the effective interest method and are added to the instrument's book value to the extent that they are not settled in the period in which they occur.

### **Disposal and modification of financial liabilities**

The Company derecognises a financial liability or a portion thereof when it has complied with the obligation contained in the liability or is legally exempted from the main liability contained in the liability either by virtue of a judicial process or by the creditor.

The difference between the book value of the financial liability or the part thereof that has been derecognised and the consideration paid – including attributable transaction costs and in which any asset assigned other than the cash or liability assumed will also be recorded – is recognised in the profit and loss account for the year in which it took place.

### **4.3 CASH AND CASH EQUIVALENTS**

Cash and other cash equivalents include cash at hand and current bank deposits in financial institutions. Other short-term, highly liquid investments are also included in this concept, as long as they are easily convertible into certain amounts of cash, and there is insignificant risk of any value change. For that purpose, investments maturing in less than three months from the date of acquisition are included. The cash flow statement includes as cash and other equivalent liquid assets bank overdrafts repayable on demand and that form part of the company's cash management. Bank overdrafts are recognised in the consolidated balance sheet as financial liabilities for debts with credit entities.

### **4.4 TAX ON PROFITS**

The tax expense or income against profits represents the current as well as deferred taxes.

The Company does not pay tax under a consolidated tax regime, by doing so individually for each of the companies.

The differences existing between the accounting result and the tax result have been considered, this being understood as the tax base of the Corporate Tax. These differences are due to the unequal definition of income and expenses in the economic and tax spheres and to the different time criteria for income and expenses in the aforementioned spheres.

The differences are classified into:

- Permanent differences, produced between the tax base of said tax and the accounting result before taxes for the financial year, which do not reverse in subsequent periods, excluding the offset losses.
- Temporary differences are those derived from the different valuation – accounting and fiscal – attributed to the assets, liabilities and certain instruments of own equity of the company, to the extent that they have an impact on the future tax burden.

As described in Note 1, the company is under the SOCIMI (Sociedades Anónimas Cotizadas de Inversión en el Mercado Inmobiliario [Public Limited Companies with Investment in the Real Estate Market]) regime regulated by Law 11/2009, of 26 October, regulating Public Limited Companies with Investment in the Real Estate Market. In this regard, in compliance with certain requirements established by said Law, the company pays a rate of 0% on Corporate Tax. Article 10 of that Law also regulates the special tax regime of partners, and particularly dividends distributed from profits or reserves on which the special tax regime established in that Law has been applied, as well as income arising from the transfer or reimbursement of capital stock of the companies opting to apply that regime.

The Board of Directors of the Company monitors compliance with the requirements established in said Law, with the objective of maintaining the aforesaid tax regime, estimating that said requirements will be fulfilled in the terms and deadlines set, and recognising the corporate income tax for the financial year in that sense.

### Deferred tax assets

According to the principle of prudence, deferred tax assets will only be recognised to the extent that it is probable that the Company will have future tax profits that allow the application of these assets. Whenever the above condition is met, a deferred tax asset will be recognised in the following cases:

- a) For deductible temporary differences;
- b) For the right to offset tax losses in subsequent periods;
- c) For deductions and other unused tax advantages not yet applied for tax purposes.

The subsidiaries of the Company, in accordance with current accounting regulations, proceed to activate the tax losses estimating that they will be able to recover all those accounted for according to future financial projections that support such activation.

### Deferred tax liabilities

A deferred tax liability is recognised for all taxable temporary differences, unless they arise from:

- a) The initial recognition of a goodwill. However, deferred tax liabilities related to a goodwill will be recorded provided they have not arisen from their initial recognition.
- b) The initial recognition of an asset or liability in a transaction that is not a business combination and also did not affect the book result or the tax base.

### Current tax assets and liabilities

The current tax is the amount that the company satisfies as a result of the tax settlements of the tax or taxes on the profit relating to a financial year. The deductions and other tax advantages in the tax quota, excluding withholdings and payments on account, as well as the tax losses to be offset from previous fiscal years and effectively applied therein, will result in a lower amount of current tax. However, those deductions and other tax advantages in the tax quota that have an economic nature similar to grants are recorded in accordance with the provisions of the standard relating to grants, donations and legacies received.

### Valuation of current and deferred tax assets and liabilities

Current tax assets and liabilities are valued at the amounts expected to be paid to or recovered from the tax authorities, in accordance with current regulations.

Deferred tax assets and liabilities shall be valued according to the types of tax expected at the time of their reversal, according to current regulations, and according to the manner in which the asset or liability is reasonably expected to be recovered or paid.

#### 4.5 INCOME AND EXPENSES

The income and expenses are allocated based on the accrual criterion regardless of the moment in which the monetary or financial current derived from them occurs.

However, the Company only records the profits realised at the year-end closing, while foreseeable risks and losses, even if they are eventual, are accounted for as soon as they are known.

Income from contracts with customers are recognised depending on the fulfilment of performance obligations with customers. However, the Company only records the profits realised at the year-end closing, while foreseeable risks and losses, even if they are eventual, are accounted for as soon as they are known.

Income from the sale of goods or services is recognised at the fair value of the compensation received or to be received as a result thereof. Cash discounts, by volume or other types of discounts, as well as interest incorporated into the nominal value of the credits, are recorded as a reduction thereof.

The Company obtains its income mainly from the interests of loans granted to its subsidiaries and the dividends received from them. The loans held by the company with its subsidiaries guarantee the development of the financing operations for their assets, from which income is obtained derived from the interests they generate. These revenues are presented as a part of the Net Turnover.

#### 4.6 PROVISIONS AND CONTINGENCIES

##### Provisions

The liabilities covering obligations present at the date of the balance sheets arising as a result of past events from which financial damages may arise from probable materialisation for the Company are recognised as provisions, the amount and time of cancellation of which are undetermined.

No amount referring to this item appears in the Balance Sheet.

##### Contingent liabilities

Possible obligations arising as a result of past events, the materialisation of which is conditioned on the occurrence, or not, of one or more future events independent of the will of the Company.

The contingent liabilities are not recognised in the annual financial statements, but rather they report on them, in accordance with the requirements of the accounting regulations.

As of the balance sheet date, there are no significant contingencies as a result of past events that may result in financial losses for the Company that are not provisioned.

#### 4.7 CRITERIA USED IN TRANSACTIONS BETWEEN RELATED PARTIES

The transactions between companies of the same group, regardless of the degree of connection between the companies pertaining to the group, will be accounted for in accordance with the general rules.

The items that are the object of the transaction are initially accounted for at fair value.

The Company carries out all its transactions with related parties to market values. Additionally, the transfer prices are adequately supported, so the Company's directors consider that there are no significant risks for this aspect from which liabilities of consideration may arise in the future.

#### 4.8 CURRENT AND NON-CURRENT ITEMS

Current assets are considered to be those related to the normal operating cycle, which in general is considered to be one year, as well as other assets whose maturity, disposal or realisation is expected to occur in the short term from the closing date of the financial year. There are financial assets held for trading that are held under the non-current assets, despite a short-term return. Assets that do not meet these requirements are classified as non-current.

Similarly, current liabilities are those related to the normal operating cycle, financial liabilities held for trading, with the exception of financial derivatives whose settlement term is greater than the year and in general all obligations whose maturity or extinction will occur in the short term. Otherwise, they are classified as non-current.

#### 4.9 MERGER AND SPIN-OFF OPERATIONS AND NON-MONETARY CONTRIBUTIONS

In merger operations, business spin-off and non-monetary contributions between companies of the group in which the parent company of the same or the parent company of a subgroup and its dependents intervene, directly or indirectly, the assets that are contributed are valued for the amount that would correspond, once the operation is performed, in the consolidated annual financial statements of the group or subgroup in accordance with the Standards for the Formulation of the Consolidated Annual Financial Statements established in RD 1159/2010, of 17 September 2010. However, in the event that consolidated annual financial statements are not formulated, under any of the exemptions provided for in the accounting regulations in force, the existing accounting values are considered before the operation is carried out in the individual annual financial statements of the contributing company.

In the event that a difference between the individual and the consolidated accounting values is revealed, said difference would be attributed against a reserve item in the beneficiary company.

The date of accounting effects for all merger and spinoff operations between companies of the group is the date of commencement of the period in which the operation is approved, provided that it is subsequent to the time when the companies were incorporated into the group; otherwise, the date of accounting effects would be that of incorporation into the group. In the case of non-monetary contributions of assets and liabilities that constitute a business, the date of accounting effects is considered to be the date of public increase of the capital increase agreement provided that the date of registration in the Commercial Registry is prior to the date on which the annual financial statements for the year in which such contributions are made.

Likewise, and in accordance with the provisions of RD 1159/2010 of 17 September, in merger and spin-off operations between companies forming part of the same group prior to the start of the immediately preceding period, no information is included on the accounting effects of the merger or spin-off in the comparative information.

### 5. Company transactions

During 2025 financial year, the Company has carried out the following company operations.

- > On January 10, 2025, and January 29, 2025, contributions of funds were made to the company Healthcare Activos Management Inversión, S.L.U. in the amount of 600 thousand euros and 15,000 thousand euros, respectively.
- > On January 30, 2025, the company Healthcare Activos Financing S.L.U. carried out the return of partners' contributions in the amount of 30,000 thousand euros.

- > On January 10, 2025, January 13, 2025, February 1, 2025, April 11, 2025, July 11, 2025, October 10, 2025, October 17, 2025 and December 19, 2025, contributions of funds were made to the company Healthcare Activos Inmobiliarios 21 S.L. for 875 thousand euros, 10 thousand euros, 261 thousand euros, 250 thousand euros, 100 thousand euros, 600 thousand euros, 300 thousand euros and 500 thousand euros, respectively.
- > On February 7, 2025, March 31, 2025, April 29, 2025, May 26, 2025, June 25, 2025, August 29, 2025, September 30, 2025, October 30, 2025, November 27, 2025, December 24, 2025 the company Healthcare Activos Inmobiliarios 21 S.L.U. carried out the return of partners' contributions in the amount of 1,195 thousand euros, 1,145 thousand euros, 280 thousand euros, 100 thousand euros, 295 thousand euros, 400 thousand euros, 800 thousand euros, 400 thousand euros, 400 thousand euros and 350 thousand euros, respectively.
- > On June 2, 2025, the company Healthcare Activos Financing S.L.U. carried out the return of partners' contributions in the amount of 32 thousand euros.
- > On July 02, 2025 and August 04, 2025, contributions of funds were made to the company Sequentialalternativa S.A. in the amounts of 219 thousand euros and 1,000 thousand euros, respectively.
- > On December 19, 2025, contributions of funds were made to the company HAIP Montijo Unipessoal LDA for 300 thousand euros.

During 2024 financial year, the Company has carried out the following company operations.

- > On January 31, 2024, the Company acquired 100% of the shares of the company Healthcare Activos Management Inversión, S.L.U., incorporated in Spain, for 528 thousand euros. This was a net asset acquisition operation which did not constitute a business.
- > On January 31, 2024, and September 5, 2024, the Company made a contribution of funds to the company HAIP Montijo Unipessoal LDA in the amount of 450 thousand and 249 thousand euros, respectively.
- > On March 2, 2024, the company Healthcare Activos Financing S.L.U. carried out the return of partners' contributions in the amount of 800 thousand euros.
- > On 26 January, 2024, 7 February, 2024, 15 April 2024, 30 April 2024, 31 May 2024, 28 June 2024, 24 July 2024, 30 August, 2024, 30 September, 2024, 28 October, 2024, 29 October, 2024, 23 December, 2024 and 30 December, 2024, the company Healthcare Activos Inmobiliarios 21 S.L.U. carried out the return of partners' contributions in the amount of 200 thousand euros, 1,600 thousand euros, 1,000 thousand euros, 125 thousand euros, 370 thousand euros, 235 thousand euros, 340 thousand euros, 200 thousand euros, 800 thousand euros, 300 thousand euros, 400 thousand euros, 745 thousand euros and 745 thousand euros, respectively.
- > On July 12, 2024 and October 11, 2024, contributions of funds were made to the company Healthcare Activos Inmobiliarios 21 S.L.U. in the amounts of 1,062 thousand euros and 1,000 thousand euros, respectively.

- > On January 29, contributions of funds were made to the company Healthcare Activos Inmobiliarios 32, S.L.U., in the amount of 2,684 thousand euros.
- > On January 29, contributions of funds were made to the company Healthcare Activos Inmobiliarios 33, S.L.U., in the amount of 1,338 thousand euros.
- > On January 29, contributions of funds were made to the company Healthcare Activos Inmobiliarios 33, S.L.U., in the amount of 1,725 thousand euros.
- > On May 15, 2024, returns of partners' contributions to the company Secuencialternativa S.A. were made in the amount 250 thousand euros.
- > On September 23, 2024 contributions of funds were made to the company Healthcare Activos Inmobiliarios 35, S.L.U., in the amount of 1.5 thousand euros.
- > On September 23, 2024 contributions of funds were made to the company Healthcare Activos Inmobiliarios 36, S.L.U., in the amount of 1.5 thousand euros.
- > On September 23, 2024 contributions of funds were made to the company Healthcare Activos Inmobiliarios 37, S.L.U., in the amount of 1.5 thousand euros.
- > On September 23, 2024 contributions of funds were made to the company Healthcare Activos Inmobiliarios 38, S.L.U., in the amount of 1.5 thousand euros.
- > On October 24, 2024, returns of partners' contributions were made by the company Healthcare Activos Financing in the amount of 2,520 thousand euros.

## 6. Long-term investments in group and associated companies

The value of the long-term investments in group and associated companies on December 31, 2025 and 2024, and the movement that has taken place in the 2025 financial year, are also shown hereinunder:

	December 31, 2024	Acquisition / Incorporation	Redemption/Contribution of funds	December 31, 2025
Healthcare Activos Financing, S.L.U.	164,840	-	(30,000)	134,840
Healthcare Activos Inmobiliarios 14, S.L.U.	8,310	-	-	8,310
Healthcare Activos Inmobiliarios 15, S.L.U.	2,475	-	-	2,475
Healthcare Activos Inmobiliarios 20, S.L.U.	8,200	-	(32)	8,168
Healthcare Activos Inmobiliarios 21, S.L.U.	11,039	-	(2,469)	8,570
Healthcare Activos Inmobiliarios 22, S.L.U.	2,486	-	-	2,486
Healthcare Activos Inmobiliarios 23, S.L.U.	6,714	-	-	6,714
Healthcare Activos Inmobiliarios 24, S.L.U.	7,039	-	-	7,039
Healthcare Activos Inmobiliarios 25, S.L.U.	6,371	-	-	6,371
Healthcare Activos Inmobiliarios 28, S.L.U.	3,171	-	-	3,171
Healthcare Activos Inmobiliarios 29, S.L.U.	19,117	-	-	19,117
Healthcare Activos Inmobiliarios 30, S.L.U.	3,759	-	-	3,759
Healthcare Activos Inmobiliarios 31, S.L.U.	7,420	-	-	7,420

## Healthcare Activos Yield SOCIMI, S.A.

Healthcare Activos Inmobiliarios 32, S.L.U.	2,687	–	–	2,687
Healthcare Activos Inmobiliarios 33, S.L.U.	1,341	–	–	1,341
Healthcare Activos Inmobiliarios 34, S.L.U.	1,728	–	–	1,728
Healthcare Activos Inmobiliarios 35, S.L.U.	5	–	–	5
Healthcare Activos Inmobiliarios 36, S.L.U.	5	–	–	5
Healthcare Activos Inmobiliarios 37, S.L.U.	5	–	–	5
Healthcare Activos Inmobiliarios 38, S.L.U.	5	–	–	5
Healthcare Activos Management Inversión, S.L.U.	528	–	15,600	16,128
HAI Montijo Unipessoal LDA	1,460	–	300	1,760
Provitae Centros Asistenciales, S.L.	2,031	–	–	2,031
Sequencial Alternativa, S.A.	7,638	–	1,219	8,857
HAI Belgium, BV	59,202	–	–	59,202
HAI Belgium 2 BV	10,942	–	–	10,942
<b>Total</b>	<b>338,518</b>	<b>–</b>	<b>(15,383)</b>	<b>323,135</b>

	December 31, 2023	Acquisition / Incorporation	Redemption/Contribution of funds	December 31, 2024
Healthcare Activos Financing, S.L.U.	168,160	–	(3,320)	164,840
Healthcare Activos Inmobiliarios 14, S.L.U.	8,310	–	–	8,310
Healthcare Activos Inmobiliarios 15, S.L.U.	2,475	–	–	2,475
Healthcare Activos Inmobiliarios 20, S.L.U.	8,200	–	–	8,200
Healthcare Activos Inmobiliarios 21, S.L.U.	16,037	–	(4,998)	11,039
Healthcare Activos Inmobiliarios 22, S.L.U.	2,486	–	–	2,486
Healthcare Activos Inmobiliarios 23, S.L.U.	6,714	–	–	6,714
Healthcare Activos Inmobiliarios 24, S.L.U.	7,039	–	–	7,039
Healthcare Activos Inmobiliarios 25, S.L.U.	6,371	–	–	6,371
Healthcare Activos Inmobiliarios 28, S.L.U.	3,171	–	–	3,171
Healthcare Activos Inmobiliarios 29, S.L.U.	19,117	–	–	19,117
Healthcare Activos Inmobiliarios 30, S.L.U.	3,759	–	–	3,759
Healthcare Activos Inmobiliarios 31, S.L.U.	7,420	–	–	7,420
Healthcare Activos Inmobiliarios 32, S.L.U.	3	–	2,684	2,687
Healthcare Activos Inmobiliarios 33, S.L.U.	3	–	1,338	1,341
Healthcare Activos Inmobiliarios 34, S.L.U.	3	–	1,725	1,728
Healthcare Activos Inmobiliarios 35, S.L.U.	3	–	2	5
Healthcare Activos Inmobiliarios 36, S.L.U.	3	–	2	5
Healthcare Activos Inmobiliarios 37, S.L.U.	3	–	2	5
Healthcare Activos Inmobiliarios 38, S.L.U.	3	–	2	5

Healthcare Activos Management Inversión, S.L.U.	-	528	-	528
HAIP Montijo Unipessoal LDA	761	-	699	1,460
Provitae Centros Asistenciales, S.L.	2,031	-	-	2,031
Sequencialalternativa, S.A.	7,388	-	250	7,638
HAI Belgium, BV	59,202	-	-	59,202
HAI Belgium 2 BV	10,942	-	-	10,942
<b>Total</b>	<b>339,605</b>	<b>528</b>	<b>(1,615)</b>	<b>338,518</b>

As a consequence of the operations described in Note 5, the Company made acquisitions of assets in the 2024 financial year by acquiring the shares outlined in the foregoing table.

The information on shares in group subsidiaries for the 2025 and 2024 financial years is shown in Annex I.

## 7. Intangible fixed assets

The breakdown of intangible fixed assets for fiscal years 2025 and 2024 is as follows:

	EDP applications	Total
<b>Cost at December 31, 2023</b>	<b>9</b>	<b>9</b>
Additions	-	-
Disposals	-	-
Transfers	-	-
<b>Cost at December 31, 2024</b>	<b>9</b>	<b>9</b>
<b>Amortisation at December 31, 2023</b>	<b>(4)</b>	<b>(4)</b>
Allocations	(3)	(3)
Disposals	-	-
Transfers	-	-
<b>Amortisation at December 31, 2024</b>	<b>(7)</b>	<b>(7)</b>
<b>Net value at December 31 2024</b>	<b>2</b>	<b>2</b>
<b>Cost at December 31, 2024</b>	<b>9</b>	<b>9</b>
Additions	-	-
Disposals	-	-
Transfers	-	-
<b>Cost at December 31, 2025</b>	<b>9</b>	<b>9</b>

<b>Amortisation at December 31, 2024</b>	<b>(7)</b>	<b>(7)</b>
Allocations	(2)	(2)
Disposals	-	-
Transfers	-	-
<b>Amortisation at December 31, 2025</b>	<b>(9)</b>	<b>(9)</b>
<b>Net value at December 31 2025</b>	<b>-</b>	<b>-</b>

Intangible fixed assets originated in the development and implementation of the Group's new website.

As of December 31, 2025, all elements accounted for in intangible fixed assets are completely amortised.

## 8. Financial assets and other receivables

The breakdown of the financial assets by classes and categories is as follows:

Thousands of euros	Short term	
	12.31.2025	12.31.2024
Trade receivables, group and associated companies (Note 14)	114	96
Loans to group companies (Note 14)	7,593	5,319
Non-current accruals	42	29
<b>Total</b>	<b>7,748</b>	<b>5,444</b>

Thousands of euros	Long term	
	12.31.2025	12.31.2024
Loans to group companies (Note 14)	115,072	93,427
<b>Total</b>	<b>115,072</b>	<b>93,427</b>

### Classification by maturity of financial assets

Following is a breakdown of the assets for the 2025 period that have a determined or determinable maturity, and of which the amounts that mature in each of the five years following the year-end closing and the rest until their last maturity must be reported.

Thousands of euros	2026	2027	2028	2029	2030	Rest	Total
Trade receivables, group and associated companies	114	-	-	-	-	-	114
Loans to group companies	7,593	115,072	-	-	-	-	122,665
Non-current accruals	42	-	-	-	-	-	42
<b>Total</b>	<b>7,748</b>	<b>115,072</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>122,820</b>

Following is a breakdown of the assets for the 2024 period that have a determined or determinable maturity, and of which the amounts that mature in each of the five years following the year-end closing and the rest until their last maturity must be reported.

Thousands of euros	2025	2026	2027	2028	2029	Rest	Total
Trade receivables, group and associated companies	96	-	-	-	-	-	96
Loans to group companies	5,319	-	93,427	-	-	-	98,746
Non-current accruals	29	-	-	-	-	-	29
<b>Total</b>	<b>5,444</b>	<b>-</b>	<b>93,427</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>98,871</b>

## 9. Financial liabilities and other payables

The breakdown of the financial liabilities by classes and categories, covering all financial liabilities at fair value with changes to profit or loss, is as follows:

Thousands of euros	Long term	
	12.31.2025	12.31.2024
Amounts payable to credit institutions	28,797	39,815
Group companies and associates, non-current (Note 14)	21,566	17,038
<b>Total</b>	<b>50,363</b>	<b>56,852</b>

Thousands of euros	Short-term	
	12.31.2025	12.31.2024
Amounts payable to credit institutions	10,768	554
Sundry creditors	625	832
<b>Total</b>	<b>11,394</b>	<b>1,386</b>

### DEBT WITH FINANCIAL INSTITUTIONS

The Company breakdown of amounts payable to credit institutions is as follows:

#### By loans

#### December 31, 2025

Thousands of euros	Limit	Formalization costs*	Maturity	Pending long-term debt**	Pending short-term debt	Short-term interests	Mortgage guarantee
Revolving line	40,000	(400)	03/31/2027	28,900	-	65	No
	<b>40,000</b>	<b>(400)</b>		<b>28,900</b>	<b>-</b>	<b>65</b>	

\*Formalization costs related with financing.

\*\* Does not include the reduction of formalization costs pending accrual at year-end.

#### December 31, 2024

Thousands of euros	Limit	Formalization costs*	Maturity	Pending long-term debt**	Pending short-term debt	Short-term interests	Mortgage guarantee
Revolving line	40,000	(400)	03/31/2027	40,000	-	93	No
	<b>40,000</b>	<b>(400)</b>		<b>40,000</b>	<b>-</b>	<b>93</b>	

\*Formalization costs related with financing.

\*\* Does not include the reduction of formalization costs pending accrual at year-end.

On March 31, 2022, the company Healthcare Activos Europe, S.A. formalized a revolving credit facility in the amount of 40 million euros for the purpose of financing Group developments, with the financial institutions Crédit Agricole Corporate and Investment Bank, (Spanish branch) and BNP Paribas, S.A. (Spanish branch), each of which holds a 50% share. On April 8, 2022, this financing was transferred to the Company through a purchase-sale contract for shares, and the transfer of rights. It was drawn at 28.9 thousand euros (40 thousand euros at December 31, 2024) at December 31, 2025. The due date is set for March 2027, by way of a single payment estimated to be made on the appropriate due date.

The formalisation costs for the loan totalled 400 thousand euros, and are shown as subtracted from the balance under the heading “Amounts payable to credit institutions”. They totalled 103 thousand euros (185 thousand euros at December 31, 2024) at December 31, 2025. The financial expense related to the allocation of such formalisation expenses accrued during financial year 2025 amounts to 82 thousand euros (80 thousand euros during financial year 2024).

The loan accrues an interest rate referenced to the Euribor plus a market margin. The interests and fees arising from this loan that were accrued in the 2025 financial year totalled 1,621 thousand euros (2,380 thousand euros during the 2024 financial year).

The loan agreement establishes various agreements and covenants, including the fulfilment of certain financial ratios that the Board of Directors estimates are fulfilled without incident at the end of financial year 2025. They are expected to be fulfilled without incident in 2026.

### By credit facilities

2025							
Thousands of euros	Limit	Formalization costs	Due date	Pending long-term debt	Pending short-term debt	Short-term interests	Mortgage guarantee
Credit facility	15,000	34	04/30/2026	–	6,076	80	No
Credit facility	5,000	10	07/30/2026	–	500	19	No
Credit facility	5,000	15	07/12/2026	–	4,028	–	No
	<b>25,000</b>	<b>59</b>		<b>–</b>	<b>10,604</b>	<b>99</b>	

2024							
Thousands of euros	Limit	Formalization costs	Due date	Pending long-term debt	Pending short-term debt	Short-term interests	Mortgage guarantee
Credit facility	15,000	(34)	04/21/2025	–	–	65	No
Credit facility	5,000	(10)	06/14/2025	–	–	24	No
Credit facility	5,000	(15)	07/12/2025	–	951	–	No
	<b>25,000</b>	<b>(59)</b>		<b>–</b>	<b>951</b>	<b>89</b>	

At year-end 2025 and 2024, the Company held the following credit facilities:

- > On April 30, 2025 the company renewed a credit facility that it had formalised on 21 April 2022 with Caixabank for the amount of 15 million euros at market interest. The interests accrued by this credit facility throughout the 2025 financial year totalled 356 thousand euros (259 thousand euros in the 2024 financial year).
- > On July 30, 2025 the Company renewed a credit facility that it had formalised on 25 April 2022 with Bankinter for the amount of 5 million euros at market interest. The interests accrued by this credit facility throughout the 2025 financial year totalled 60 thousand euros (79 thousand euros in the 2024 financial year).
- > On July 12, 2025 the Company renewed a credit facility that it had formalised on July 12, 2023 with Banc Sabadell for the amount of 5 million euros at market interest. The interests accrued by this credit facility throughout the 2025 financial year totalled 131 thousand euros (176 thousand euros in the 2024 financial year).

The net cash flow shown in the Cash Flow Statement of the 2025 financial year as collections and payments for financial liability instruments originated by amounts due to credit institutions, totalled 1,446 thousand negative euros, 27,563 thousand for reception of new loans, and 29,009 thousand euros to pay for amortisation of various loans.

The net cash flow shown in the Cash Flow Statement of the 2024 financial year as collections and payments for financial liability instruments originated by amounts due to credit institutions, totalled 6,672 thousand euros, 19,172 thousand for reception of new loans, 12,500 thousand euros to pay for amortisation of various loans.

## 9.2 CLASSIFICATION BY MATURITY OF FINANCIAL LIABILITIES

Following is a breakdown of the financial liabilities for the 2025 financial year that have a determined or determinable maturity, and of which the amounts that mature in each of the five years following the year-end closing and the rest until their last maturity must be reported.

Thousands of euros	2026	2027	2028	2029	2030	Rest	Total
Amounts payable to credit institutions	10,789	28,879	-	-	-	-	39,668
Debt formalization costs	(21)	(82)	-	-	-	-	(103)
Sundry creditors	625	-	-	-	-	-	625
Amounts due to group companies	-	21,566	-	-	-	-	21,566
<b>Total</b>	<b>11,394</b>	<b>50,363</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>61,757</b>

Following is a breakdown of the financial liabilities for the 2024 financial year that have a determined or determinable maturity, and of which the amounts that mature in each of the five years following the year-end closing and the rest until their last maturity must be reported.

Thousands of euros	2025	2026	2027	2028	2029	Rest	Total
Amounts payable to credit institutions	636	-	39,918	-	-	-	40,554
Debt formalization costs	(82)	(80)	(23)	-	-	-	(185)
Sundry creditors	832	-	-	-	-	-	832
Amounts due to group companies	-	-	17,038	-	-	-	17,038
<b>Total</b>	<b>1,386</b>	<b>(80)</b>	<b>56,932</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>58,238</b>

## 10. Shareholders' equity and own funds

### 10.1 SHARE CAPITAL AND SHARE PREMIUM

At December 31, 2025 and 2024, the Parent company's share capital totalled 174,194 thousand euros represented by 174,193,682 ordinary shares, of 1 euro par value each, all of the same class, completely subscribed and paid.

At December 31, 2025 and 2024, the share premium of the Company totalled 85,593 thousand euros.

Over the 2025 and 2024 financial years, no variations in share premiums have been carried out.

At December 31, 2025 the shareholders holding significant stakes of the share capital of the Company are:

	<u>% share</u>
One Hundred and Twenty Investment Company	49.358%
REI Spain B.V.	37.855%
Durham County Council Pension Fund	2.374%
CBRE European Venture Fund	4.748%
TFL Trustee Company Limited	4.381%
Healthcare Activos Management Patrimonio, S.L.	0.627%
Other investors	0.657%

### OTHER EQUITY HOLDERS' CONTRIBUTIONS

As of December 31, 2025 the Company held 117,702 thousand euros (116,848 thousand euros at December 31, 2024) under the heading "Other equity holders' contributions."

As of November 20, 2025, Company shareholders have made contributions in the amount of 5,359 thousand euros (17,699 thousand euros in the 2024 business year) under the heading "Other equity holders' contributions".

### 10.3 OTHER RESERVES

The breakdown of reserves at December 31, 2025 and 2024 is as follows:

<u>Thousands of euros</u>	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Legal reserve	2,388	1,358
Amortized capital reserve	(641)	(641)
<b>Total</b>	<b>1,747</b>	<b>717</b>

#### 10.3.1 Legal reserve

Provision will be made for the legal reserve pursuant to Article 274 of the Consolidated Text of the Capital Companies Act, which establishes that in any event, a figure equal to 10% of the profit for the financial year will be assigned to the legal reserve until it reaches at least 20% of the share capital.

The legal reserve is not distributable and if used to compensate for losses, in the event that there are no other sufficient available reserves for this purpose, it must be restored with future profits.

At December 31, 2025 and 2024, the Company has not made provision to this reserve with the minimum limit established in the Consolidated Text of the Capital Companies Act.

Pursuant to Law 11/2009, which regulates Real Estate Investment Trusts (Sociedades Anónimas Cotizadas de Inversión en el Mercado Inmobiliario - SOCIMI), the legal reserve of companies that have

chosen to apply the special tax regime established in this law cannot exceed 20% of the share capital.

The articles of association cannot establish any restricted reserve other than the one previously described.

#### 10.4 DIVIDENDS

During financial year 2025 the Company has carried out the following dividend distributions:

- > On January 30, 2025, an extraordinary dividend was distributed in favour of the shareholders of the Company by means of distribution of the profit from the 2024 financial year in the amount of 617 thousand euros, and through distribution of the interim profit of the 2025 financial year in the amount of 3,789 thousand euros. These dividends were disbursed on February 10, 2025.

The Liquidity Statement is as follows:

#### Estado de liquidez

Limite de distribución de dividendos a cuenta Limit on distribution of interim dividends	
Resultado contable estimado a fecha de distribución (1) Estimated accounting result at distribution date (1)	14.212.110,56
Pérdidas de ejercicios anteriores (2) Losses from previous years (2)	0
Estimación del Impuesto a pagar sobre dicho resultado (3) Estimated tax payable on said result (3)	0
Dotación a reservas legales o estatutarias (4) Allocation to legal or statutory reserves (4)	1.085.574,91
Limite de distribución de dividendos a cuenta (1+2-3-4) Limit on distribution of interim dividends (1+2-3-4)	13.126.535,65
Dividendo a cuenta ya distribuido (5) Interim dividend already distributed (5)	8.655.604,00
Limite de distribución de dividendos a cuenta (1-2-3-4-5) Limit on distribution of interim dividends (1-2-3-4-5)	4.470.931,65
Cuadro de liquidez disponible Available liquidity table	
Disponible a 30 de enero de 2025 (Tesorería) Available as of July 2, 2024 (Treasury)	11.070.861,68
Pagos previstos a c/p por todos los conceptos Scheduled short-term payments for all concepts	3.784.687,39
Cobros previstos a c/p por todos los conceptos Scheduled short-term collections for all concepts	5.905.461,84
Pagos previstos por dividendo a cuenta Scheduled payments for interim dividends	4.406.677,65
<b>SALDO DISPONIBLE FINAL</b> <b>FINAL AVAILABLE BALANCE</b>	<b>8.784.958,48</b>

- > On April 29, 2025, an extraordinary dividend was distributed in the Company shareholders' favour by refund of the Other equity holders' contributions in the amount of 4,505 thousand euros. These dividends were disbursed on May 09, 2025.
- > On July 01, 2025, an extraordinary dividend was distributed in favour of the shareholders of the Company by means of an interim dividend for the profits of the 2025 financial year in the amount of 4,505 thousand euros. These dividends were disbursed on July 10, 2025.

The Liquidity Statement is as follows:

<b>Estado de liquidez</b>	
Resultado contable a la fecha de distribución	
Estimated accounting result at distribution date	9.414.311,17
Pérdidas de ejercicios anteriores (2)	
Losses from previous years (2)	-
Estimación del Impuesto a pagar sobre dicho resultado (3)	
Estimated tax payable on said result (3)	-
Dotación a reservas legales o estatutarias (4)	
Allocation to legal or statutory reserves (4)	-
<b>Límite de distribución de dividendos a cuenta (1+2-3-4)</b>	
<b>Limit on distribution of interim dividends (1+2-3-4)</b>	<b>9.414.311,17</b>
Dividendo a cuenta ya distribuido (5)	
Interim dividend already distributed (5)	-
<b>Límite de distribución de dividendos a cuenta (1-2-3-4-5)</b>	
<b>Limit on distribution of interim dividends (1-2-3-4-5)</b>	<b>9.414.311,17</b>
<b>Cuadro de liquidez disponible</b>	
<b>Available liquidity table</b>	
Disponible a 10 de julio de 2025 (Tesorería)	
Available as of July 10, 2025 (Treasury)	8.172.136,34
Pagos previstos a c/p por todos los conceptos	
Scheduled short-term payments for all concepts	3.695.416,92
Cobros previstos a c/p por todos los conceptos	
Scheduled short-term collections for all concepts	6.456.828,00
Pagos previstos por dividendo a cuenta	
Scheduled payments for interim dividends	4.504.791,67
<b>SALDO DISPONIBLE FINAL</b>	
<b>FINAL AVAILABLE BALANCE</b>	<b>6.428.755,75</b>

- > On October 28, 2025, an extraordinary dividend was distributed in favour of the shareholders of the Company by means of an interim dividend for the profits of the 2025 financial year in the amount of 4,505 thousand euros. These dividends were disbursed on November 06, 2025.

The Liquidity Statement is as follows:

<b>Liquidity statement</b>	
Interim dividend distribution limit	
Interim dividend distribution limit	
Estimated accounting result at distribution date (1)	13,867,681.83
Estimated accounting result at distribution date (1)	
Losses from previous financial years	
Losses from previous financial years (2)	0
Estimated tax payable on aforesaid result (3)	
Estimated tax payable on aforesaid result (3)	0
Provision to legal or statutory reserves (4)	0
<b>Interim dividend distribution limit (1+2-3-4)</b>	<b>13,867,681.83</b>
<b>Interim dividend distribution limit (1+2-3-4)</b>	
Interim dividend already distributed (5)	
Interim dividend already distributed (5)	8,294,699.39
<b>Interim dividend distribution limit (1-2-3-4-5)</b>	<b>5,572,982.44</b>
<b>Available liquidity statement</b>	
<b>Available liquidity statement</b>	
Available at July 2, 2024 (Cash)	6,471,653.17
Available as of July 2, 2024 (Cash)	
S.T. payments planned for all concepts	
Short-term payments planned for all concepts	5,244,670.65
S.T. collections planned for all concepts	
Short-term collections planned for all concepts	
Payments for interim dividend planned	4,504,791.67
Payments for interim dividend planned	
<b>FINAL AVAILABLE BALANCE</b>	<b>3,649,012.90</b>

During financial year 2024 the Company carried out the following dividend distributions:

- > On January 30, 2024, an extraordinary dividend was distributed in favour of the shareholders of the Company by means of the return of other equity holders' contributions in the amount of 3,217 thousand euros, and by an interim dividend for the profits of the 2023 financial year in the amount of 1,060 thousand euros. These dividends were disbursed on February 07, 2024.

The Liquidity Statement is as follows:

### Liquidity statement

#### Interim dividend distribution limit

Estimated accounting result at distribution date (1)	5,870,618.
Losses from previous financial years (2)	0
Estimated tax payable on aforesaid result (3)	0
Provision to legal or statutory reserves (4)	510,547
Interim dividend distribution limit (1+2-3-4)	4,597,619
Interim dividend already distributed (5)	0
Interim dividend distribution limit (1-2-3-4-5)	4,597,619

#### Available liquidity statement

Available at October 11, 2023 (Cash)	3,556,742
Payments planned for all concepts	42,800,000
Collections planned for all concepts	70,400,000
Payments for dividend charged to reserves	0
Payments for interim dividend planned	3,935,791
<b>ENDING BALANCE AVAILABLE</b>	<b>27,220.951</b>

- > On April 25, 2024, an extraordinary dividend was distributed in the Company shareholders' favour by refund of the Other equity holders' contributions in the amount of 4,328 thousand euros. These dividends were disbursed on May 3, 2024.
- > On July 2, 2024, an extraordinary dividend was distributed in favour of the shareholders of the Company by means of an interim dividend for the profits of the 2024 financial year in the amount of 4,328 thousand euros. These dividends were disbursed on July 9, 2024.

The Liquidity Statement is as follows:

<b>Liquidity statement</b>	
Interim dividend distribution limit	
Interim dividend distribution limit	
Estimated accounting result at distribution date (1)	7,306,545.52
Estimated accounting result at distribution date (1)	
Losses from previous financial years (2)	0
Estimated tax payable on aforesaid result (3)	0
Provision to legal or statutory reserves (4)	730,654.55
Interim dividend distribution limit (1+2-3-4)	6,575,890.97
Interim dividend already distributed (5)	0
Interim dividend distribution limit (1-2-3-4-5)	6,575,890.97
Available liquidity statement	
Available at July 2, 2024 (Cash)	16,427,573.67
S.t. payments planned for all concepts	13,008,774.55
S.t. collections planned for all concepts	15,093,770.56
Payments for interim dividend planned	4,327,802.00
ENDING BALANCE AVAILABLE	14,184,767.68

- > On October 29, 2024, an extraordinary dividend was distributed in favour of the shareholders of the Company by means of an interim dividend for the profits of the 2024 financial year in the amount of 4,328 thousand euros. These dividends were disbursed on November 6, 2024.

The Liquidity Statement is as follows:

**Liquidity statement**

Interim dividend distribution limit	
Interim dividend distribution limit	
Estimated accounting result at distribution date (1)	7,306,545.52
Estimated accounting result at distribution date (1)	
Losses from previous financial years (2)	0
Estimated tax payable on aforesaid result (3)	0
Provision to legal or statutory reserves (4)	730,654.55
Interim dividend distribution limit (1+2-3-4)	6,575,890.97
Interim dividend already distributed (5)	0
Interim dividend distribution limit (1-2-3-4-5)	6,575,890.97
Available liquidity statement	
Available at July 2, 2024 (Cash)	16,427,573.67
S.t. payments planned for all concepts	13,008,774.55
S.t. collections planned for all concepts	15,093,770.56
Payments for interim dividend planned	4,327,802.00
ENDING BALANCE AVAILABLE	14,184,767.68

**11. Public Entities and tax situation****11.1 BALANCES WITH PUBLIC ADMINISTRATIONS**

The composition of current balances with Public Entities is as follows:

Thousands of euros	12.31.2025		12.31.2024	
	Debtor	Creditor	Debtor	Creditor
Taxation authorities, receivables: VAT recoverable	-	-	-	175
Tax authorities, payable: VAT payable	-	338	-	-
Tax receivables for withholding and payments on account	826	-	934	-
Taxation authorities, payables: withholding tax	-	1,001	-	913
Social Security bodies	-	2	-	1
<b>Total</b>	<b>826</b>	<b>1,340</b>	<b>934</b>	<b>1,089</b>

On December 17, 2019, the Board of Directors of the Company agreed to the acceptance from January 1, 2020 of the group of entities whose parent is the Company, opting for the application of the Special Regime of the Value Added Tax of the Group of Entities, provided for in Chapter IX of Heading IX of Law 37/1992, of 28 December. As of December 31, 2023, Healthcare Activos Financing, S.L.U., and the

following subsidiaries belonged to said group: Healthcare Activos Inmobiliarios 14, S.L.U., Healthcare Activos Inmobiliarios 15, S.L.U., Healthcare Activos Inmobiliarios 20, S.L.U. , Healthcare Activos Inmobiliarios 21, S.L.U. , Healthcare Activos Inmobiliarios 22, S.L.U. , Healthcare Activos Inmobiliarios 23, S.L.U. , Healthcare Activos Inmobiliarios 24, S.L.U. , Healthcare Activos Inmobiliarios 25, S.L.U. , Healthcare Activos Inmobiliarios 29, S.L.U. , Healthcare Activos Inmobiliarios 30, S.L.U. , Healthcare Activos Inmobiliarios 31, S.L.U. , Healthcare Activos Inmobiliarios 32, S.L.U., Healthcare Activos Inmobiliarios 33, S.L.U., and Healthcare Activos Inmobiliarios 34, S.L.U., Healthcare Activos Inmobiliarios 35, S.L.U., and Healthcare Activos Inmobiliarios 36, S.L.U.

On December 9, 2024, the Company agreed to include in the group, effective January 1, 2025, the companies Healthcare Activos Inmobiliarios 28, S.L.U Healthcare Activos Inmobiliarios 37, S.L.U., Healthcare Activos Inmobiliarios 38, S.L.U., Healthcare Activos Inmobiliarios 39, S.L.U., Healthcare Activos Inmobiliarios 40, S.L.U., Healthcare Activos Management Inversión, S.L.U..

## TAX ON PROFITS

As stated in Note 1, on September 13, 2019, the Company notified the State Tax Administration Agency that they were applying the special SOCIMI (REIT) tax regime. The application of this regime has effects for the entire tax periods of 2025 and 2024.

At December 31, 2025 and 2024, the Group does not keep any amount recorded for any type of deferred assets and liabilities (including negative tax bases) or deductions related to corporate income tax.

### 11.3 PERIODS NOT YET VERIFIED BY THE TAX AUTHORITIES

According to current legal provisions, tax assessments cannot be considered definitive until they have been inspected by the tax authorities or until the statute of limitations has elapsed.

In general, for the main applicable taxes, the Company has pending inspection by the tax authorities for all fiscal years since its incorporation. Due to the different interpretations of the applicable fiscal regulations, there could be contingent liabilities, which are not susceptible to objective quantification. However, Management considers that the materialisation of these would be unlikely and in any case defensible, and that they would not reach significant amounts in relation to the annual financial statements and it has not been considered necessary to provide any extra provision for this concept.

## 12. Income and expenses

### 12.1 NET REVENUE AND OTHER OPERATING INCOME

The heading “Net revenue” corresponds to the Dividends received by the company from its subsidiaries, in addition to the interests related with loans that it holds with them (see Note 14).

The heading “Other operating income” corresponds to expenses booked under the heading “Other operating expenses” and that the company has re-invoiced to its subsidiaries (see note 14).

### 12.2 OTHER OPERATING EXPENSES

The details of the main items included in this heading are as follows:

<u>Thousands of euros</u>	<u>2025</u>	<u>2024</u>
Independent professional services	58	353
Insurance premiums	99	72

Bank services	14	4
Other Expenditures	206	238
<b>Total</b>	<b>378</b>	<b>667</b>

The heading Services from independent professionals includes management fees invoiced by the managing company of the Group for an amount of 15 thousand euros, in addition to payment of personnel cost assumed by the managing company for an amount of 78 thousand euros (15 and 75 thousand euros in the 2024 financial year) under the management fee agreement formalised between the management company and the Company.

In the 2025 financial year, insurance costs totalled 303 thousand euros (344 thousand euros in the 2024 financial year), of which 204 thousand euros (273 thousand in the 2024 financial year) were re-invoiced by the Company to some of its subsidiaries (see Note 14). These re-invoiced expenses are accounted for under the heading "Other Expenditures".

### 13. Information on the average period of payment to suppliers during financial year. Third additional provision. Duty of information of Law 15/2010, of 5 July

We provide hereinunder the information required by the Third Additional Provision of Law 15/2010, of 5 July (amended by Second Final Provision of Law 31/2014, of 3 December), prepared as per the Spanish Accounting and Audit Institute (ICAC) Resolution of January 29, 2016, on the information to include in the Notes to the Annual Accounts regarding the average supplier payment term in business operations.

<u>Days</u>	<u>2025</u>	<u>2024</u>
Average period of payment to suppliers	10	13
Ratio of transactions paid	10	13
Ratio of transactions pending payment	12	0

<u>Thousands of euros</u>	<u>2025</u>	<u>2024</u>
Total payments made	534	554
Total outstanding payments	8	0

In the 2025 financial year, invoices have been paid in the amount of 534 thousand euros (standing for 100% of the total payments to suppliers) in a period shorter than the maximum set in the regulations on payment default.

In the 2024 financial year, invoices have been paid in the amount of 554 thousand euros (standing for 89% of the total payments to suppliers) in a period shorter than the maximum set in the regulations on payment default.

<u>Thousands of euros</u>	<u>2025</u>	<u>2024</u>
Monetary volume paid	534	554
% over the total payments to suppliers	100%	%
Number of invoices paid	67	51
% over the number of invoices paid to suppliers	100%	87.9%

Pursuant to the ICAC Resolution, the calculation of the Average period of payment to suppliers is based on business operations linked to the delivery of goods or services, accrued since the entry into force of Law 31/2014, of 3 December.

Suppliers are considered, for the exclusive purposes of providing the information stipulated in this Resolution, to be those trade creditors for debts with suppliers of goods or services, included in the item "Trade creditors and other payables" of the current liabilities on the attached balance sheet.

"Average period of payment to suppliers" is considered to be the period that transpires from the delivery of the goods or services by the supplier and material payment of the operation.

As of the publication of the aforementioned Law, and up to the present, the maximum legal term applicable to the Company pursuant to Law 11/2013 of 26 July is 30 days (unless certain conditions established in the law are met, which would allow the extension of the payment period to 60 days).

## 14. Transactions and balances with related parties

### 14.1 TRANSACTIONS WITH GROUP, ASSOCIATED AND RELATED PARTIES

The breakdown of transactions that have taken place in the 2025 and 2024 financial years is shown in Annex II.

The costs re-invoiced to subsidiaries mainly correspond to insurance for damages and civil liability of the buildings owned by the subsidiaries of the Company.

The Company owns 100% of the equity units of the companies of the group with which it has carried out transactions during fiscal years 2025 and 2024, with the exception of Provitae Centros Asistenciales, S.L., which holds 50% of the shares at the close of the 2025 and 2024 financial years.

The company received dividends from the profits of the following subsidiaries in the 2025 financial year:

Company	Date approved	Type	Thousands of euros
Healthcare Activos Financing, S.L.U.	01/20/2025	Interim dividend 2024	2,845
Healthcare Activos Inmobiliarios 21, S.L.U.	01/20/2025	Interim dividend 2024	261
Healthcare Activos Inmobiliarios 23, S.L.U.	01/20/2025	Interim dividend 2024	24
Healthcare Activos Inmobiliarios 24, S.L.U.	01/20/2025	Interim dividend 2024	227
Healthcare Activos Management Inversión, S.L.U.	06/17/2025	Interim dividend 2025	150
Healthcare Activos Financing, S.L.U.	06/02/2025	Profit Dividend 2024	449
Healthcare Activos Inmobiliarios 20, S.L.U.	06/02/2025	Profit Dividend 2024	(32)
Healthcare Activos Inmobiliarios 21, S.L.U.	06/02/2025	Profit Dividend 2024	9
Healthcare Activos Inmobiliarios 23, S.L.U.	06/02/2025	Profit Dividend 2024	2
Healthcare Activos Inmobiliarios 24, S.L.U.	06/02/2025	Profit Dividend 2024	15
Healthcare Activos Financing, S.L.U.	06/17/2025	Interim dividend 2025	3,345

Company	Date approved	Type	Thousands of euros
Healthcare Activos Inmobiliarios 20, S.L.U.	06/17/2025	Interim dividend 2025	41
Healthcare Activos Inmobiliarios 21, S.L.U.	06/17/2025	Interim dividend 2025	645
Healthcare Activos Inmobiliarios 23, S.L.U.	06/17/2025	Interim dividend 2025	46
Healthcare Activos Inmobiliarios 24, S.L.U.	06/17/2025	Interim dividend 2025	121
Healthcare Activos Management Inversión, S.L.U.	10/17/2025	Interim dividend 2025	66
Healthcare Activos Financing, S.L.U.	10/17/2025	Interim dividend 2025	3,013
Healthcare Activos Inmobiliarios 20, S.L.U.	10/17/2025	Interim dividend 2025	32
Healthcare Activos Inmobiliarios 21, S.L.U.	10/17/2025	Interim dividend 2025	330
Healthcare Activos Inmobiliarios 23, S.L.U.	10/17/2025	Interim dividend 2025	10
Healthcare Activos Inmobiliarios 24, S.L.U.	10/17/2025	Interim dividend 2025	36
Healthcare Activos Management Inversión, S.L.U.	12/17/2025	Interim dividend 2025	67
Healthcare Activos Financing, S.L.U.	12/17/2025	Interim dividend 2025	1,825
Healthcare Activos Inmobiliarios 20, S.L.U.	12/17/2025	Interim dividend 2025	20
Healthcare Activos Inmobiliarios 21, S.L.U.	12/17/2025	Interim dividend 2025	706
Healthcare Activos Inmobiliarios 23, S.L.U.	12/17/2025	Interim dividend 2025	16
Healthcare Activos Inmobiliarios 24, S.L.U.	12/17/2025	Interim dividend 2025	42
<b>Total</b>			<b>14,311</b>

The company received dividends from the profits of the following subsidiaries in the 2024 financial year:

Company	Date approved	Type	Thousands of euros
Healthcare Activos Financing, S.L.U.	06/17/2024	Ordinary dividend 2024	2,145
Healthcare Activos Inmobiliarios 20, S.L.U.	06/17/2024	Ordinary dividend 2024	169
Healthcare Activos Inmobiliarios 21, S.L.U.	06/17/2024	Ordinary dividend 2024	218
Healthcare Activos Financing, S.L.U.	06/17/2024	Interim dividend 2024	3,738
Healthcare Activos Inmobiliarios 20, S.L.U.	06/17/2024	Interim dividend 2024	42
Healthcare Activos Inmobiliarios 21, S.L.U.	06/17/2024	Interim dividend 2024	561
Healthcare Activos Inmobiliarios 24, S.L.U.	06/17/2024	Interim dividend 2024	11
Healthcare Activos Financing, S.L.U.	10/17/2024	Interim dividend 2024	2,166
Healthcare Activos Inmobiliarios 20, S.L.U.	10/17/2024	Interim dividend 2024	20
Healthcare Activos Inmobiliarios 21, S.L.U.	10/17/2024	Interim dividend 2024	88
Healthcare Activos Inmobiliarios 23, S.L.U.	10/17/2024	Interim dividend 2024	30
Healthcare Activos Inmobiliarios 24, S.L.U.	10/17/2024	Interim dividend 2024	64
<b>Total</b>			<b>9.252</b>

Over the 2025 financial year, the Company has collected interests from loans granted to subsidiaries totalling 6,383 thousand euros (5,180 during the 2024 financial year).

#### 14.2 BALANCES WITH GROUP, ASSOCIATED AND RELATED PARTIES

The breakdown of balances with group, associated and related companies as of 31 December 2025 and 2024 are shown in Annex III.

### 14.2.1. Long-term balances

#### **Creditor balances**

At December 31, 2025, the long-term debtor balances with group companies totalled 21,566 thousand euros (17,038 thousand euros at December 31, 2024).

At December 31, 2024, the Company held a creditor balance with Healthcare Activos Financing, S.L.U. originating from Healthcare Activos Inmobiliarios 26, S.L.U. the company absorbed by Healthcare Activos Financing, S.L.U. This loan, dated March 31, 2022, was granted for an amount of 6,002 thousand euros to the Company to manage the Group's cash surpluses following the refinancing transaction that took place on the same date. At December 31, 2024, the principal of this loan totalled 915 thousand euros. Although the due date was set for March 31, 2027, this loan was amortised in advance on June 17, 2025. This loan accrued a market interest rate.

At December 31, 2025, the Company held a creditor balance with Healthcare Activos Financing, S.L.U. originating from a loan of an amount not to exceed 15 million euros formalised on April 17, 2023. The principal of this loan at year-end 2025 totals 14,784 thousand euros (12,248 thousand euros at year-end 2024). This loan accrues a market interest rate.

At December 31, 2025 and 2024 the company holds a creditor balance with Healthcare Activos Inmobiliarios 29 S.L.U., Healthcare Activos Inmobiliarios 31 S.L.U., Healthcare Activos Inmobiliarios 35 S.L.U., Healthcare Activos Inmobiliarios 36 S.L.U., Healthcare Activos Inmobiliarios 37 S.L.U., Healthcare Activos Inmobiliarios 38 S.L.U., Healthcare Activos Inmobiliarios 39 S.L.U. and Healthcare Activos Management Inversión S.L.U. via the Cash Pooling system, by which balances of the subsidiaries are transferred daily to the Parent Company.

#### **Debtor balances**

At December 31, 2025, the long-term debtor balances with group companies totalled 115,072 thousand euros (93,427 thousand euros at December 31, 2024).

As described in Note 9, in financial year 2022 the Company formalized a revolving credit facility of 40 million euros meant to finance the developments of its Subsidiaries. The company manages the cash of its subsidiaries through the granting of long-term credit facilities with maximums determined depending on the projects each company carries out and their duration, at a market interest rate. The drawn balance of these credit facilities, as well as the interests accrued and not paid at the closure of the 2025 and 2024 business years are described in Annex III with the companies Healthcare Activos Inmobiliarios 14, S.L.U., Healthcare Activos Inmobiliarios 15, S.L.U., Healthcare Activos Inmobiliarios 20, S.L.U., Healthcare Activos Inmobiliarios 22, S.L.U., Healthcare Activos Inmobiliarios 23, S.L., Healthcare Activos Inmobiliarios 24, S.L.U., Healthcare Activos Inmobiliarios 25, S.L.U., Healthcare Activos Inmobiliarios 28, S.L.U., Healthcare Activos Inmobiliarios 30, S.L.U., Healthcare Activos Inmobiliarios 32, S.L.U., Healthcare Activos Inmobiliarios 33, S.L.U., and Healthcare Activos Inmobiliarios 34, S.L.U.

The Company also holds long-term loans with the companies Healthcare Activos Inmobiliarios 29, S.L.U., Healthcare Activos Inmobiliarios 31, S.L.U., and Healthcare Activos Inmobiliarios 39 S.L.U.

granted to these companies to finance asset purchases. The due date of these loans was set for March 31, 2027. They accrue a market interest.

At December 31, 2025 the company holds a creditor balance with Healthcare Activos Inmobiliarios 40 S.L.U., by the Cash Pooling system, through which the balances of the subsidiaries are transferred daily to their Parent Company.

On April 8, 2022, the Company signed a receivable loan with the company Sequencialternativa, S.A. in the amount of 4,366 thousand euros. At December 31, 2024, the principal of this loan totalled 504 thousand euros. Although the due date was set for March 31, 2027, this loan was amortised in advance in the 2025 financial year. This loan accrued a market interest rate.

#### 14.2.2 Short-term balances

##### **Creditor balances**

At December 31, 2025, the long-term debtor balances with group companies totalled 57 thousand euros (0 thousand euros at December 31, 2024).

At 31 December 2025, the short-term creditor balances held by the Company totalled 57 thousand euros to be paid for VAT with the companies Healthcare Activos Inmobiliarios 15, S.L.U., Healthcare Activos Inmobiliarios 22, S.L.U., Healthcare Activos Inmobiliarios 28, S.L.U., Healthcare Activos Inmobiliarios 30, S.L.U., Healthcare Activos Inmobiliarios 33, S.L.U., and Healthcare Activos Inmobiliarios 34, S.L.U., given the fact that the company is head of the VAT tax group (see Note 11.1).

##### **Debtor balances**

At December 31, 2025, the long-term debtor balances with group companies totalled 7,707 thousand euros (5,415 thousand euros at December 31, 2024).

At financial year-ends 2025 and 2024, the debtor balances were chiefly attributable to interests accrued and not paid at the end of the financial year, a consequence of the loans with subsidiaries Healthcare Activos Inmobiliarios 29 S.L.U, Healthcare Activos Inmobiliarios 31 S.L.U, Sequencialternativa S.A., and Healthcare Activos Inmobiliarios 39 S.L.U., described in Note 14.2.1, as well as the balances of the debtor account of the VAT Group account, and customer pending collection derived from re-invoicing of expenses to subsidiaries.

On December 18, 2020, the Company acquired 50% of the equity units of Provitae Centros Asistenciales, S.L. from Maquavit Inmuebles, S.L.U., subsidiary fully owned by the company Healthcare Activos Yield Growth, S.L.U. at that time. As a result of said sale, the Company subrogated in the position that Maquavit Inmuebles, S.L.U. held with respect to receivable balances from the acquired company (Provitae Centros Asistenciales, S.L.) for an amount of 1,081 thousand euros. Over the financial years 2025 and 2024 the company has augmented this loan, with the principal and interests receivable totalling 1,066 and 256 thousand euros, respectively, at December 31, 2025 (1,041 and 224 thousand euros, respectively, at 31 December 2024).

### In if through 14.2.3 Other current payables

The Company had no outstanding balance for payment to its shareholders at December 31, 2025 and December 31, 2024.

### 14.2.4 Remuneration to Directors and Senior Management

During fiscal years 2025 and 2024 the Directors and Senior Management of the Company have not earned compensation. No severance pay or payments based on equity instruments have been accrued during the 2025 and 2024 financial years.

No loan or advance payments have been granted to the members of the Board of Directors.

No pension obligations or life insurance have been contracted with respect to any member of the Board of Directors. However, the Company maintains liability insurance for Managers and Directors.

### 14.2.5 Information regarding conflict of interest situations for the directors

At the end of financial years 2025 and 2024, pursuant to Article 229 of the Capital Companies Act, some members of company management held posts or roles in companies with the same, analogous or complementary type of activity. These situations were duly notified and validated pursuant to the terms of Art. 230 of the TRLSC (Consolidated Text of the Capital Companies Act).

During fiscal years 2025 and 2024, the Parent Company's directors have not carried out with it or with other companies of the group transactions outside the ordinary traffic or in conditions other than those of the market.

## 15. Other information

### 15.1 AUDIT FEES

The fees for account auditing provided to the Company by the principal auditor KPMG Auditores, S.L. and other entities related to it, are set forth below:

Thousands of euros	2025	2024
Audit services	61	74
<b>Total auditing and related services</b>	<b>61</b>	<b>74</b>
Tax advisory services	-	18
Other services	48	113
<b>Total auditing and related services</b>	<b>109</b>	<b>205</b>

The auditing services billed to the Company totalled 61 and 74 thousand euros in the 2025 and 2024 financial years, respectively.

### 15.2 ENVIRONMENTAL AND CLIMATE CHANGE INFORMATION

Given the nature of the Company's operations, it has no responsibilities, expenses, assets, provisions and contingencies of an environmental nature or related to greenhouse gases that could be significant in relation to the equity, financial position or results thereof. For this reason, specific breakdowns are

not included in this annual report on the annual financial statements regarding information on environmental issues.

The Group of which the Company is the parent company has an ESG Committee responsible for identifying, evaluating and managing climate change risks. Although the Group has an ESG Action Plan through which it is committed to measuring its carbon footprint, climate change is not considered to have a significant impact on these financial statements. The Group adheres to the Principles of Responsible Investment (PRI) by which it agrees to integrate ESG criteria in the investment processes, and therefore takes into account the risks they could represent.

### **15.3 OTHER RELEVANT POST-CLOSING INFORMATION**

No relevant events have occurred following the close of the financial year that affect the Company's financial situation that are not already portrayed in the balance sheet, or about which information has not been included in another Note to the Accounts.

## **16. Regulatory requirements arising from the status SOCIMI, Law 11/2009, amended by Law 16/2012**

In compliance with the Reporting Obligations derived from the status of Socimi, established in Article 11 of Law 11/2009, of 26 October, which regulates the Public Limited Investment Companies Listed on the Real Estate Market, the aspects included in Annex IV are indicated.

Barcelona, March 12, 2026

**Annex I – Shares in group companies as of December 31, 2025 (in Thousands of euros)**

Name	Address	Acquisition /incorporation date	% of Equity Holding	Capital	Equity holders' contributions	Reserves	2025 Profit/loss	Profit or loss, prior years	Interim dividends	Total net equity	Net book value
Healthcare Activos Financing, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	08/01/2019	100%	3	49,059	45,058	9,084	-	(8,183)	95,021	134,840
Healthcare Activos Inmobiliarios 14, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	5,879	1	(1,086)	(2,081)	-	2,715	8,310
Healthcare Activos Inmobiliarios 15, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	2,353	-	(688)	(1,306)	-	302	2,475
Healthcare Activos Inmobiliarios 20, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	6,025	1	101	(1,247)	(93)	4,789	8,168
Healthcare Activos Inmobiliarios 21, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	6,814	1	1,851	(1,059)	(1,681)	5,575	8,570
Healthcare Activos Inmobiliarios 22, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	12/01/2020	100%	3	2,483	-	(758)	(667)	-	1,061	2,486
Healthcare Activos Inmobiliarios 23, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	5,732	1	80	(1,135)	(72)	4,607	6,714
Healthcare Activos Inmobiliarios 24, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	6,261	1	212	(836)	(200)	5,441	7,039
Healthcare Activos Inmobiliarios 25, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	4,089	-	(174)	(722)	-	3,196	6,371

**Annex I – Shares in group companies as of December 31, 2025 (in Thousands of euros)**

Name	Address	Acquisition /incorporation date	% of Equity Holding	Capital	Equity holders' contributions	Reserves	2025 Profit/loss	Profit or loss, prior years	Interim dividends	Total net equity	Net book value
Healthcare Activos Inmobiliarios 29, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	06/21/2022	100%	3	19,114	-	48	(24)	-	19,140	19,117
Healthcare Activos Inmobiliarios 30, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	06/21/2022	100%	3	3,756	-	(451)	(484)	-	2,824	3,759
Healthcare Activos Inmobiliarios 31, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	06/21/2022	100%	3	7,417	-	20	(25)	-	7,415	7,420
Healthcare Activos Inmobiliarios 32, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	10/19/2022	100%	3	2,684	-	(426)	(860)	-	1,401	2,687
Healthcare Activos Inmobiliarios 33, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	10/19/2022	100%	3	1,338	-	(355)	(501)	-	486	1,341
Healthcare Activos Inmobiliarios 34, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	12/18/2023	100%	3	1,725	-	(460)	(553)	-	716	1,728
Healthcare Activos Inmobiliarios 35, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	01/13/2023	100%	3	2	-	(1)	(1)	-	2	5
Healthcare Activos Inmobiliarios 36, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	01/19/2023	100%	3	2	-	(1)	(1)	-	2	5

**Annex I – Shares in group companies as of December 31, 2025 (in Thousands of euros)**

Name	Address	Acquisition /incorporation date	% of Equity Holding	Capital date	Equity holders' contributions	Reserves	2025 Profit/loss	Profit or loss, prior years	Interim dividends	Total net equity	Net book value
Healthcare Activos Inmobiliarios 37, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	10/19/2022	100%	3	2	-	(1)	(2)	-	2	5
Healthcare Activos Inmobiliarios 38, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	10/19/2022	100%	3	2	-	(1)	(1)	-	3	5
Healthcare Activos Inmobiliarios 39, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	12/18/2020	100%	-	300	-	(24)	(12)	-	264	1,760
Healthcare Activos Management Inversión, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	01/31/2025	100%	3	15,825	-	320	(490)	(283)	15,375	16,128
Provitae Centros Asistenciales, S.L.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	50%	3,157	-	197	(33)	(891)	-	2,430	2,031
Sequencialternativa, S.A.	Rua de Baden- Powell, 3, 5000- 198, Vila Real (Portugal)	12/21/2022	100%	50	2,654	10	(75)	(1,672)	-	967	8,857
Healthcare Activos Inmobiliarios 40, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	12/21/2022	100%	-	-	-	(198)	(128)	-	(326)	59,202
HAI Belgium 2 NV	Turnhoutsebaan 277 B-2100 Deurne (Antwerp), Belgium.	09/06/2023	100%	10,942	-	-	(1,175)	(1,891)	-	7,876	10,942
<b>Total</b>				<b>14,212</b>	<b>145,494</b>	<b>45,268</b>	<b>5,467</b>	<b>(17,243)</b>	<b>(10,512)</b>	<b>182,334</b>	<b>323,135</b>

**Annex I – Shares in group companies as of December 31, 2024 (in Thousands of euros)**

Name	Address	Acquisition /incorporation date	% of Equity Holding	Capital	Equity holders' contributions	Reserves	2024 Profit/loss	Profit or loss, prior years	Interim dividends	Total net equity	Net book value
Healthcare Activos Finacing, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	08/01/2019	100%	3	79,059	45.058	9,198	-	(5.905)	127.414	164,840
Healthcare Activos Inmobiliarios 14, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	5,879	1	(972)	(1,110)	-	3,801	8,310
Healthcare Activos Inmobiliarios 15, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	2,353	-	(392)	(914)	-	1,050	2,475
Healthcare Activos Inmobiliarios 20, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	6,057	1	29	(1,247)	(62)	4,781	8,200
Healthcare Activos Inmobiliarios 21, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	9,283	1	1,288	(1,059)	(649)	8,866	11,039
Healthcare Activos Inmobiliarios 22, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	12/01/2020	100%	3	2,483	-	(377)	(290)	-	1,819	2,486
Healthcare Activos Inmobiliarios 23, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	5,732	-	57	(1,135)	(30)	4,626	6,714
Healthcare Activos Inmobiliarios 24, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	6,261	-	318	(836)	(75)	5,671	7,039
Healthcare Activos Inmobiliarios 25, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	100%	3	4,089	-	(279)	(443)	-	3,370	6,371

## Annex I – Shares in group companies as of December 31, 2024 (in Thousands of euros)

Name	Address	Acquisition /incorporation date	% of Equity Holding	Capital	Equity holders' contributions	Reserves	2024 Profit/loss	Profit or loss, prior years	Interim dividends	Total net equity	Net book value
Healthcare Activos Inmobiliarios 28, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	07/27/2023	100%	3	1,980	-	(418)	(233)	-	1,333	3,171
Healthcare Activos Inmobiliarios 29, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	06/21/2022	100%	3	19,114	-	(325)	(140)	-	18,652	19,117
Healthcare Activos Inmobiliarios 30, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	06/21/2022	100%	3	3,756	-	(231)	(254)	-	3,275	3,759
Healthcare Activos Inmobiliarios 31, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	06/21/2022	100%	3	7,417	-	(609)	(249)	-	6,562	7,420
Healthcare Activos Inmobiliarios 32, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	10/19/2022	100%	3	2,684	-	(557)	(304)	-	1,827	2,687
Healthcare Activos Inmobiliarios 33, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	10/19/2022	100%	3	1,338	-	(285)	(217)	-	840	1,341
Healthcare Activos Inmobiliarios 34, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	12/18/2023	100%	3	1,725	-	(304)	(249)	-	1,175	1,728
Healthcare Activos Inmobiliarios 35, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	01/13/2023	100%	3	2	-	(0)	(1)	-	3	5
Healthcare Activos Inmobiliarios 36, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	01/19/2023	100%	3	2	-	(0)	(1)	-	3	5

**Annex I – Shares in group companies as of December 31, 2024 (in Thousands of euros)**

Name	Address	Acquisition /incorporation date	% of Equity Holding	Capital	Equity holders' contributions	Reserves	2024 Profit/loss	Profit or loss, prior years	Interim dividends	Total net equity	Net book value
Healthcare Activos Inmobiliarios 37, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	10/19/2022	100%	3	2	-	(2)	-	-	3	5
Healthcare Activos Inmobiliarios 38, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	10/19/2022	100%	3	2	-	(1)	-	-	3	5
Healthcare Activos Inmobiliarios 39, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	12/18/2020	100%	53	850	-	(261)	(588)	-	3	1,460
Healthcare Activos Management Inversión, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	01/31/2025	100%	3	225	-	(226)	(264)	-	(262)	528
Provitae Centros Asistenciales, S.L.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	04/08/2022	50%	6,314	-	394	(26)	(1,694)	-	2,465	2,031
Sequencialternativa, S.A.	Rua de Baden-Powell, 3, 5000-198, Vila Real (Portugal)	12/21/2022	100%	50	1,435	10	(330)	(1,342)	-	(177)	7,638
Healthcare Activos Inmobiliarios 40, S.L.U.	Calle Serrano, 21, sexto piso, puerta B, 28001, Madrid	12/21/2022	100%	8,504	-	160	(313)	3,066	-	11,416	59,202
HAI Belgium 2 NV	Turnhoutsebaan 277 B-2100 Deurne (Antwerp), Belgium.	09/06/2023	100%	10,942	-	-	(1,271)	(625)	-	7,754	10,942
<b>Total</b>				<b>25,926</b>	<b>161,728</b>	<b>45,625</b>	<b>3,711</b>	<b>(10,129)</b>	<b>(6,721)</b>	<b>216,273</b>	<b>338,518</b>

## Annex II – Transactions with group, multigroup and associated companies in the 2025 financial year – in Thousands of euros

Company	Type of Transaction	Income/Expense	Transaction Amount / Income	Transaction Amount / Expenditure	Valuation method
Healthcare Activos Financing, S.L.U.	Financial Interest	Financial Expense	-	(880)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 14, S.L.U.	Financial Interest	Turnover	865	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 15, S.L.U.	Financial Interest	Turnover	517	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 20, S.L.U.	Financial Interest	Turnover	40	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 22, S.L.U.	Financial Interest	Turnover	577	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 23, S.L.U.	Financial Interest	Turnover	9	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 24, S.L.U.	Financial Interest	Turnover	2	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 25, S.L.U.	Financial Interest	Turnover	359	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 28, S.L.U.	Financial Interest	Turnover	440	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 29, S.L.U.	Financial Interest	Financial Expense	-	(97)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 29, S.L.U.	Financial Interest	Turnover	905	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 30, S.L.U.	Financial Interest	Turnover	291	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 31, S.L.U.	Financial Interest	Financial Expense	-	(60)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 31, S.L.U.	Financial Interest	Turnover	938	-	Comparable Uncontrolled Price

Company	Type of Transaction	Income/Expense	Transaction Amount / Income	Transaction Amount / Expenditure	Valuation method
Healthcare Activos Inmobiliarios 32, S.L.U.	Financial Interest	Turnover	641	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 33, S.L.U.	Financial Interest	Turnover	180	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 34, S.L.U.	Financial Interest	Turnover	286	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 35, S.L.U.	Financial Interest	Financial Expense	-	(o)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 36, S.L.U.	Financial Interest	Financial Expense	-	(o)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 37, S.L.U.	Financial Interest	Financial Expense	-	(o)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 38, S.L.U.	Financial Interest	Financial Expense	-	(o)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 39, S.L.U.	Financial Interest	Financial Expense	-	(o)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 39, S.L.U.	Financial Interest	Turnover	300	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 40, S.L.U.	Financial Interest	Turnover	3	-	Comparable Uncontrolled Price
Healthcare Activos Management Inversión, S.L.U.	Financial Interest	Financial Expense	-	(39)	Comparable Uncontrolled Price
Provitae Centros Asistenciales, S.L.	Financial Interest	Turnover	31	-	Comparable Uncontrolled Price
Sequencialternativa, S.A.	Financial Interest	Turnover	1	-	Comparable Uncontrolled Price
<b>Total</b>			<b>6,383</b>	<b>(1,076)</b>	

## Annex II – Transactions with group, multigroup and associated companies in the 2024 financial year – in Thousands of euros

Company	Type of Transaction	Income/Expense	Transaction Amount / Income	Transaction Amount / Expenditure	Valuation method
Healthcare Activos Financing, S.L.U.	Financial Interest	Financial Expense	-	(653)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 29, S.L.U.	Financial Interest	Financial Expense	-	(58)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 31, S.L.U.	Financial Interest	Financial Expense	-	(42)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 35, S.L.U.	Financial Interest	Financial Expense	-	(o)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 36, S.L.U.	Financial Interest	Financial Expense	-	(o)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 37, S.L.U.	Financial Interest	Financial Expense	-	(o)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 38, S.L.U.	Financial Interest	Financial Expense	-	(o)	Comparable Uncontrolled Price
Healthcare Activos Management Inversión, S.L.U.	Financial Interest	Financial Expense	-	(3)	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 14, S.L.U.	Financial Interest	Turnover	644	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 15, S.L.U.	Financial Interest	Turnover	232	-	Comparable Uncontrolled Price

Company	Type of Transaction	Income/Expense	Transaction Amount / Income	Transaction Amount / Expenditure	Valuation method
Healthcare Activos Inmobiliarios 20, S.L.U.	Financial Interest	Turnover	26	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 22, S.L.U.	Financial Interest	Turnover	213	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 23, S.L.U.	Financial Interest	Turnover	324	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 24, S.L.U.	Financial Interest	Turnover	238	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 25, S.L.U.	Financial Interest	Turnover	195	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 28, S.L.U.	Financial Interest	Turnover	252	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 29, S.L.U.	Financial Interest	Turnover	945	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 30, S.L.U.	Financial Interest	Turnover	67	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 31, S.L.U.	Financial Interest	Turnover	973	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 32, S.L.U.	Financial Interest	Turnover	391	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 33, S.L.U.	Financial Interest	Turnover	111	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 34, S.L.U.	Financial Interest	Turnover	136	-	Comparable Uncontrolled Price
Healthcare Activos Inmobiliarios 39, S.L.U.	Financial Interest	Turnover	342	-	Comparable Uncontrolled Price
Provitae Centros Asistenciales, S.L.	Financial Interest	Turnover	42	-	Comparable Uncontrolled Price
Sequencialternativa, S.A.	Financial Interest	Turnover	49	-	Comparable Uncontrolled Price
<b>Total</b>			<b>5,180</b>	<b>(756)</b>	

**Annex III – Balances with group, multigroup and associated companies in the 2025 financial year – in Thousands of euros**

Company	CIF (Tax ID Code)	Type of relationship	% of equity holding	Long term		Short-term	
				Debtor Balance	Creditor Balance	Debtor Balance	Creditor Balance
Healthcare Activos Financing, S.L.U.	B88108170	Group Company	100%	-	14,784	373	-
Healthcare Activos Inmobiliarios 14, S.L.U.	B88228275	Group Company	100%	14,730	-	11	-
Healthcare Activos Inmobiliarios 15, S.L.U.	B88228283	Group Company	100%	11,177	-	-	6
Healthcare Activos Inmobiliarios 20, S.L.U.	B88440383	Group Company	100%	680	-	10	-
Healthcare Activos Inmobiliarios 21, S.L.U.	B88526678	Group Company	100%	-	-	14	-
Healthcare Activos Inmobiliarios 22, S.L.U.	B88526660	Group Company	100%	12,176	-	-	17
Healthcare Activos Inmobiliarios 23, S.L.U.	B88526652	Group Company	100%	79	-	11	-
Healthcare Activos Inmobiliarios 24, S.L.U.	B88526645	Group Company	100%	37	-	16	-
Healthcare Activos Inmobiliarios 25, S.L.U.	B88526637	Group Company	100%	7,029	-	13	-
Healthcare Activos Inmobiliarios 28, S.L.U.	B42742486	Group Company	100%	9,589	-	4	3
Healthcare Activos Inmobiliarios 29, S.L.U.	B10841468	Group Company	100%	13,400	3,408	2,516	-
Healthcare Activos Inmobiliarios 30, S.L.U.	B10841450	Group Company	100%	7,572	-	4	4
Healthcare Activos Inmobiliarios 31, S.L.U.	B10841443	Group Company	100%	13,895	2,029	2,425	-
Healthcare Activos Inmobiliarios 32, S.L.U.	B72638141	Group Company	100%	5,316	-	14	-
Healthcare Activos Inmobiliarios 33, S.L.U.	B72638133	Group Company	100%	5,955	-	-	13
Healthcare Activos Inmobiliarios 34, S.L.U.	B72638125	Group Company	100%	8,994	-	-	13
Healthcare Activos Inmobiliarios 35, S.L.U.	B44575132	Group Company	100%	-	2	-	-

	Company	CIF (Tax ID Code)	Type of relationship	% of equity holding	Long term		Short-term	
					Debtor Balance	Creditor Balance	Debtor Balance	Creditor Balance
Healthcare Activos Inmobiliarios 36, S.L.U.		B44575124	Group Company	100%	-	2	-	-
Healthcare Activos Inmobiliarios 37, S.L.U.		B56388655	Group Company	100%	-	2	-	-
Healthcare Activos Inmobiliarios 38, S.L.U.		B56388788	Group Company	100%	-	3	-	-
Provitae Centros Asistenciales, S.L.		B83141226	Related company	50%	-	-	1,322	-
Healthcare Activos Inmobiliarios 39, S.L.U.		B19984160	Group Company	100%	4,250	282	943	0
Healthcare Activos Management Inversión, S.L.U.		B09697939	Group Company	100%	-	1,053	31	-
Healthcare Activos Inmobiliarios 40, S.L.U.		B16479610	Group Company	100%	193	-	-	-
HAI Belgium 2 BV		BE 0805612714	Group Company	100%	-	-	-	-
<b>Total</b>					<b>115,072</b>	<b>21,566</b>	<b>7,707</b>	<b>57</b>

**Annex III – Balances with group, multigroup and associated companies in the 2024 financial year – in Thousands of euros**

Company	CIF (Tax ID Code)	Type of relationship	% of equity holding	Long term		Short-term	
				Debtor Balance	Creditor Balance	Debtor Balance	Creditor Balance
Healthcare Activos Financing, S.L.U.	B88108170	Group Company	100%	-	14,078	77	-
Healthcare Activos Inmobiliarios 14, S.L.U.	B88228275	Group Company	100%	15,985	-	-	-
Healthcare Activos Inmobiliarios 15, S.L.U.	B88228283	Group Company	100%	6,900	-	-	-
Healthcare Activos Inmobiliarios 20, S.L.U.	B88440383	Group Company	100%	760	-	3	-
Healthcare Activos Inmobiliarios 21, S.L.U.	B88526678	Group Company	100%	-	-	3	-
Healthcare Activos Inmobiliarios 22, S.L.U.	B88526660	Group Company	100%	7,964	-	-	-
Healthcare Activos Inmobiliarios 23, S.L.U.	B88526652	Group Company	100%	277	-	4	-
Healthcare Activos Inmobiliarios 24, S.L.U.	B88526645	Group Company	100%	(232)	-	3	-
Healthcare Activos Inmobiliarios 25, S.L.U.	B88526637	Group Company	100%	5,016	-	2	-
Healthcare Activos Inmobiliarios 28, S.L.U.	B42742486	Group Company	100%	7,268	-	-	-
Healthcare Activos Inmobiliarios 29, S.L.U.	B10841468	Group Company	100%	13,400	1,737	-	-
Healthcare Activos Inmobiliarios 30, S.L.U.	B10841450	Group Company	100%	2,299	-	-	-
Healthcare Activos Inmobiliarios 31, S.L.U.	B10841443	Group Company	100%	13,895	1,044	-	-
Healthcare Activos Inmobiliarios 32, S.L.U.	B72638141	Group Company	100%	10,244	-	-	-
Healthcare Activos Inmobiliarios 33, S.L.U.	B72638133	Group Company	100%	1,905	-	-	-
Healthcare Activos Inmobiliarios 34, S.L.U.	B72638125	Group Company	100%	2,763	-	-	-
Healthcare Activos Inmobiliarios 35, S.L.U.	B44575132	Group Company	100%	-	3	-	-
Healthcare Activos Inmobiliarios 36, S.L.U.	B44575124	Group Company	100%	-	3	-	-
Healthcare Activos Inmobiliarios 37, S.L.U.	B56388655	Group Company	100%	-	2	-	-
Healthcare Activos Inmobiliarios 38, S.L.U.	B56388788	Group Company	100%	-	3	-	-
Provitae Centros Asistenciales, S.L.	B83141226	Related company	50%	-	-	-	-
Sequencialternativa, S.A.	5,1E+08	Group Company	100%	504	-	-	-
Healthcare Activos Inmobiliarios 39, S.L.U.	B19984160	Group Company	100%	4,479	-	-	-

Company	CIF (Tax ID Code)	Type of relationship	% of equity holding	Long term		Short-term	
				Debtor Balance	Creditor Balance	Debtor Balance	Creditor Balance
Healthcare Activos Management Inversión, S.L.U.	B09697939	Group Company	100%	-	168	4	-
HAI Belgium, BV	BE0795127410	Group Company	100%	-	-	-	-
HAI Belgium 2 BV	BE 0805612714	Group Company	100%	-	-	-	-
<b>Total</b>				<b>93,427</b>	<b>17,038</b>	<b>96</b>	<b>-</b>

#### Annex IV – Regulatory requirements arising from the status of SOCIMI, for the 2025 financial year

##### Observation requirement

Information on the 2025 financial year

Observation requirement	There are no reserves from fiscal years prior to the application of the tax regime established by the Law, as the Company was incorporated in 2019, the financial year in which it requested application of the aforementioned tax regime.			
	Subject to tax rate of 0%	Subject to tax rate of 19%	Subject to general tax rate	Tax-exempt
	Thousands of euros			
a) Reserves arising from periods prior to application of the tax regime established in this Law.	-	-	-	20
b) Reserves from fiscal years in which the tax regime established in this Law has been applied from in this Law has been applied, differentiating the portion of income that comes from income subject to the tax rate of 0%, or 19%, from those that, where appropriate, have been taxed at the general tax rate.	-	387	-	33,105
	-	415	-	-
	-	-	-	45,415
	-	-	-	28,154

2024 Financial Year	-	556	-	10,154
2025 Financial Year	-	1,030	-	854
	-	<b>2,388</b>	-	<b>117,702</b>

c) Dividends distributed from profits for each fiscal year in which the tax regime established in this Law has been applicable, differentiating the portion that comes from income subject to the tax rate of 0% or 19%, from those that, where appropriate, have been taxed at the general tax rate.

The Company has distributed the following dividends, charged to profits:

Thousands of euros	Subject to tax rate of 19%	Not subject to tax rate of 19%	Type
December 20, 2020	-	1,947	Interim dividend
April 6, 2021	-	1,336	Ordinary dividend
April 6, 2021	-	411	Interim dividend
November 8, 2021	-	1,947	Interim dividend
December 14, 2021	-	1,302	Interim dividend
April 26, 2022	7	72	Interim dividend
November 3, 2023	-	3,936	Interim dividend
February 7, 2024	-	1,060	Interim dividend
May 3, 2024	-	4,328	Interim dividend
July 9, 2024	-	4,328	Interim dividend

Healthcare Activos Yield SOCIMI, S.A.

November 6, 2024	-	4,328	Interim dividend
February 10, 2025	-	4,407	Interim dividend
July 10, 2025	-	4,505	Interim dividend
November 6, 2025	-	4,505	Interim dividend
		<b>38,610</b>	

d) In the case of distribution of dividends charged to reserves, designation of the fiscal year from which the applied reserve is applicable and whether they have been taxed at the 0%, 19% or general rate tax rate.

The company Healthcare Activos Yield Socimi S.A. distributed the following dividends, charged to Reserves:

Thousands of euros	Subject to tax rate of 19%	Not subject to tax rate of 19%	Type
April 6, 2020	-	1,532	Charged to the share premium
April 6, 2020	-	1	Charged to the share premium
July 25, 2020	-	1,532	Charged to the share premium
September 30, 2020	-	607	Charged to the share premium
November 13, 2020	-	420	Charged to the share premium
June 30, 2021	-	1,947	Charged to the share premium
March 23, 2022	-	1,931	Charged to the share premium
June 28, 2022	-	2,982	Charged to contributions
October 26, 2022	-	2,982	Charged to contributions
February 13, 2023	-	3,175	Charged to contributions
April 11, 2023	-	3,936	Charged to contributions
July 3, 2023	7	3,936	Charged to contributions
February 7, 2024	-	3,217	Charged to contributions
May 9, 2025	-	4,505	Charged to contributions

32,703

e) Date of the dividend distribution agreement referred to in points c) and d) above.	The dates of the distribution of dividends mentioned in c) and d) are indicated in their respective sections.
f) Date of acquisition of the properties intended for the lease and of the equity units in the capital of entities referred to in paragraph 1 of article 2 of this Law.	The Company does not have properties directly. If through its subsidiaries, their acquisition dates are described in Annex I.
g) Identification of the asset that is computed within 80% referred to in paragraph 1 of article 3 of this Law.	The assets that count within 80%, as referred to in section 1 of article 3 of the Law, are those related to urban buildings devoted to leasing activity, owned by the subsidiaries listed in section f).
h) Reserves from fiscal years in which the special tax regime established in this Law has been applicable, which have been arranged in the tax period, that is not for its distribution or to offset losses, identifying fiscal year from which such reserves originate.	There are no reserves from fiscal years prior to the application of the tax regime established by the Law that are not used for its distribution or to offset losses.

## Directors' report

### ECONOMIC EVOLUTION OF THE BUSINESS

Healthcare Activos Yield SOCIMI, S.A. is the head company of a group making up a leading platform specialising in real estate assets in the social/healthcare and dependence sector in Iberia, with a portfolio of leased assets carefully selected under long-term contracts with top-tier European operators.

On December 23, 2021, the Company signed an agreement with a consortium of global institutional investors to invest in the platform, and support its future long-term growth. Within the same framework, an agreement was signed for the refinancing of the Group's debt, of which the Company is the head, through the cancellation of its outstanding debt, and the signing of a new loan agreement with BNP Paribas and Credit Agricole. On March 31, 2022 the conditions precedent established in these agreements were met. Consequently, the institutional investors REI Spain, B.V., took shares in the Company's capital. Durham County Council Pension Fund (Durham), Tfl Trustee Company Limited, trustee of Tfl Pension Fund (Transport for London), CBRE European Venture Fund (CBRE EVF) and One Hundred and Twenty Investment Company LLC (Abu Dhabi Sovereign Wealth Fund).

Concurrently, the Company acquired a portfolio of 14 buildings located mainly on the Iberian peninsula, owned by the Spanish company Healthcare Activos Investment S.A. and the Portuguese company HAACP Lda., with a total valuation of approximately 203 million euros.

The operation described made it possible for the Company and its subsidiaries to continue with the international expansion plan, having situated the market value of the investments managed by the Group of which the Company is head at as much as 918 million euros at December 31, 2025, and with a presence in Spain, Portugal and Belgium.

During the 2025 financial year, the Company reached a turnover amount of 20,694 thousand euros, with the turnover in the 2024 financial year amounting to 14,432 thousand euros. The 2025 and 2024 financial year turnover was comprised of interests from loans granted to subsidiaries and income received by the Company as dividends received from its subsidiaries.

At the end of financial years 2025 and 64, the Group, of which the Company is the head, has a total of 64 assets with a capacity of more than 7,563 beds, carefully selected in locations with solid supply-demand fundamentals. All assets are leased to reputable operators under long-term contracts.

On October 1, 2020, the shares of the Company were technically listed in the "Euronext Access" stock market in Paris.

The social/healthcare and dependency sector has proven to be an essential infrastructure in a society marked by progressive ageing of the population at the domestic and EU levels as well as higher life expectancies. This reality is driving increased demand for residential facilities for elders, specialized care centres and social/health care services. The shortage of infrastructures adapted to the needs of an aging population is becoming a critical challenge. The Group is committed to the development of modern, efficient facilities that guarantee an optimal environment for the long-term care of elderly individuals and chronic patients.

In this scenario, the Group's foundations are worth highlighting: excellent carefully selected locations, leases to first-class social/health care operators with high rent coverage and triple net long-term rental contracts guaranteed by the Parent Company, with fixed income and indexed to the CP, or another price updating index applicable in the country where the asset is located. The solidity of the Group's results and treasury projections are noteworthy.

Also noteworthy is the Group's commitment to the ESG strategy, which in 2023 has meant the group's debt being rated as Social by the Moody's Agency.

The company has long-term commitments to support European healthcare operators in their expansion plans, cooperating with them through real estate infrastructure. Furthermore, the Company collaborates closely with the different operators of the healthcare sector contributing to the development of projects, measures and sector regulatory framework to achieve the best treatment and care of people, thus generating sustainable and long-term value for all interest groups.

## INVESTMENTS

During the 2025 financial year the Group's subsidiaries invested 34 million euros in assets (76 million euros in the 2024 financial year), with a market value at year-end 2025 totalling 918 million euros (867 million euros at year-end 2024), and plans to increase its investments in the short term in order to expand its assets portfolio in the healthcare sector during the 2026 financial year.

## RESEARCH AND DEVELOPMENT ACTIVITIES

The Company has not carried out research and development activities during financial years 2025 and 2024.

## ACQUISITION OF OWN SHARES AND EQUITY UNITS

At the end of financial years 2025 and 2024, the Company has no own shares.

## FINANCIAL RISK FACTORS

The Company's activities do not present significant concentrations of financial risks.

## DERIVATIVE FINANCIAL INSTRUMENTS

During financial years 2025 and 2024, the Company has not contracted derivative financial instruments in order to hedge the interest rate risk.

## AVERAGE PAYMENT PERIOD

The Group's average payment period during financial years 2025 and 2024 has been 10 and 13 days.


## RELEVANT POST-CLOSING INFORMATION


No relevant events have occurred following the close of the financial year that affect the Company's financial situation that are not already portrayed in the balance sheet, or about which information has not been included in another Note to the Accounts.


## Healthcare Activos Yield SOCIMI, S.A.

On March 12, 2026, the Directors of Sociedad Healthcare Activos Yield SOCIMI, S.A., in compliance with the requisites established in Article 253.2 of the Consolidated Text of the Capital Companies Act and in Article 37 of the Commercial Code, have met and hereby prepare the annual financial statements for the financial year spanning from January 1, 2025 to December 31, 2025. The annual financial statements are comprised of the Balance Sheet, the Profit and Loss Account, the Statement of Retained Earnings, the Cash Flow Statement, the Annual Report and the Directors' Report.

Signees:


**Firmado por:**  
  
C387C4957C6942D...  
Mr. Jorge Guarner Muñoz

**Firmado por:**  
  
32CF98877D91497...  
Mr. Alberto Fernández Sabater

**DocuSigned by:**  
  
C9A972D775E640A...  
Mr. Anthony Mohr

**DocuSigned by:**  
  
45BA5379D44D445...  
Ms. Khadija Benzit

**Signé par :**  
  
BC23CC78C06949C...  
Mr. Alexander van Riel

**DocuSigned by:**  
  
2A105A6538FF469...  
Ms. Line Verroken